

# MINISTRY OF HEALTH INFLUENZA PANDEMIC PREPAREDNESS AND RESPONSE PLAN

Prepared: July 2006 Revision 2: November 2, 2007 - Dr. Marion Bullock DuCasse, MOH.

# CONTENTS

|              | Page(s)                                 |    |
|--------------|---|----|
| Abbreviation | s and Acronyms                          | 3  |
| Background   |   | 5  |
| Introduction |   | 6  |
| Aims and Ob  | ojectives                               | 7  |
| Authority    |   | 9  |
| Activation   |   | 10 |
| Prevention   |   | 11 |
| Mitigation   |   | 12 |
| Preparednes  | S                                       | 12 |
| Phases of th | e Plan                                  | 14 |
| Designation  | and Determination of Phases of the Plan | 17 |
| Response P   | lan                                     | 18 |
| -            | Phase 1                                 | 19 |
| -            | Phase 2                                 | 26 |
| -            | Phase 3                                 | 30 |
| -            | Phase 4                                 | 37 |
| -            | Phase 5                                 | 42 |
| -            | Phase 6                                 | 47 |
| Deactivation |   | 55 |
| Debriefing   |   | 55 |
| Final Report |   | 55 |
| Acknowledge  | ement                                   | 55 |

# ABBREVIATIONS AND ACRONYMS

| AI       | Avian Influenza  |
|----------|--|
| CAREC    | Caribbean Epidemiology Centre                              |
| CARICOM  | Caribbean Community  |
| CE       | Chief Epidemiologist                                       |
| СМО      | Chief Medical Officer                                      |
| CNO      | Chief Nursing Officer                                      |
| DFH      | Director of Family Health                                  |
| DPC      | Disease Prevention and Control                             |
| DVS      | Division of Veterinary Services                            |
| EAD/Prep | Emergency Animal Disease Preparedness Plan                 |
| EDMSSB   | Emergency, Disaster Management and Special Services Branch |
| EH       | Environmental Health                                       |
| FAO      | Food and Agriculture Organization                          |
| НЕРА     | High Efficiency Particulate Air                            |
| HMH&E    | Honourable Minister of Health                              |
| HPAI     | Highly Pathogenic Avian Influenza                          |
| HPE      | Health Promotion and Education                             |
| HPI      | Human Pandemic Influenza                                   |
| HP&P     | Health Promotion and Protection                            |
| HRM&CS   | Human Resource Manager and Corporate Services              |
| HSP&I    | Health Services Planning & Integration                     |
| IC       | Information and Communication                              |

| IFA                  | Immuno-Fluorescent Antibody                                 |
|----------------------|---|
| MOA                  | Ministry of Agriculture                                     |
| MOH&E                | Ministry of Health and Environment                          |
| MOH&E NIPP Committee | MOH&E National Influenza Pandemic Preparedness<br>Committee |
| NCH                  | National Chest Hospital                                     |
| NEADCOM              | National Emergency Animal Disaster Committee                |
| NEPA                 | National Environmental and Planning<br>Association          |
| NPHL                 | National Public Health Laboratory                           |
| ODPEM                | Office of Disaster Preparedness and Emergency<br>Management |
| OIE                  | World Organization for Animal Health                        |
| РАНО                 | Pan American Health Organization                            |
| PCR                  | Polymerase Chain Reaction                                   |
| PS                   | Permanent Secretary   |
| RTD                  | Regional Technical Director                                 |
| SARS                 | Severe Acute Respiratory Syndrome                           |
| SITU                 | Systems Information Technology Unit                         |
| SMO(H)               | Senior Medical Officer of (Health)                          |
| SR                   | Standards & Regulations                                     |
| WHO                  | World Health Organization                                   |
| UHWI                 | University Hospital of the West Indies                      |
| UWI                  | University of the West Indies                               |
|                      |   |

#### BACKGROUND

Influenza is a highly contagious viral disease of the respiratory tract. It derives its public health significance from the rapidity by which epidemics evolve and spread amongst the community, and the associated widespread morbidity and serious complications, which may be fatal.

Historically, there were three (3) influenza pandemics in the twentieth century: "Spanish influenza" in 1918, "Asian influenza" in 1957 and "Hong Kong influenza" in 1968. The 1918 pandemic killed an estimated forty (40) to fifty (50) million people worldwide. That pandemic, which was exceptional, is considered one of the deadliest disease events in human history. Subsequent pandemics were much milder with an estimated two (2) million deaths in 1957 and one (1) million deaths in 1968.

While there has not been a pandemic in almost three (3) decades, there have been recent outbreaks of a highly pathogenic type of influenza that has given rise to a growing concern.

Since 1961, it has been known that a highly pathogenic avian influenza caused by H5 and H7 subtypes of Type A influenza virus, exists among wildfowl, the natural reservoirs. The H5N1 virus has been particularly virulent, causing severe and fatal disease in domesticated birds. Until 1996, the focus of this disease was avian as it did not typically affect humans. However, in 1997, the first cases of human infections as a result of contact with infected poultry were recorded. In that outbreak in Hong Kong, eighteen (18) persons suffered severe respiratory illness, six (6) of whom died.

More recent outbreaks of the disease among poultry began in late 2003 and quickly spread so that by January 2004, eight (8) Asian countries were affected. At that time, Thailand and Vietnam reported their first human cases, with the latter recording sixty (60) human cases resulting in thirty five (35) deaths – a case fatality rate of 58%. Millions of birds were culled and by March 2004, the outbreak was considered to be under control and of minimal threat to humans as investigations linked most human cases to direct contact with infected poultry. However, in June 2004, new outbreaks of animal infections were reported in nine (9) Asian countries. The disease is now endemic in Asia and has spread to Eastern Europe and Northern Africa.

As of November 5, 2007, there have been 334 confirmed human cases of avian influenza reported to the WHO from twelve (12) countries, of which 205 have died, to yield a case fatality rate of more than 61%. It is suspected that the burden of disease is greater than that reported as it has been shown that the disease may occur in the absence of respiratory symptoms.

The disease has become more pathogenic and dangerous to both human and animal life. It has been detected in dead wild fowl, which had previously tolerated infection. It has expanded its animal host range to include pigs and tigers. It has become hardier, able to survive up to six (6) days at above tropical temperatures. Finally, studies of infections in eleven (11) family clusters showed cases with no contact with infected birds in two (2) of the clusters. The other cases had provided care to the index case, leading to a suspicion that human-to-human transmission may have occurred. As yet, there is no evidence that such transmission can be sustained.

These several factors have fuelled concerns that an influenza pandemic might be imminent. Given the constantly changing nature of the virus, the occurrence of a pandemic defies prediction of the timing and severity of the disease. Therefore, it is imperative that immediate steps be taken to forestall the occurrence of such an event. Studies have shown that the risk factors for avian influenza are several and varied, national and individual. Therefore, multi-disciplinary, multi-sectoral approaches are required to manage outbreaks and prevent a pandemic.

Given the success of the global intervention that successfully averted a potential severe acute respiratory syndrome (SARS) pandemic, the World Health Organization has launched a global initiative to have every member country in a state of preparedness for a pandemic of avian influenza (AI). This initiative employs the strategies, which worked in, and the lessons learnt from the SARS experience, in a bid to prevent an outbreak of H5N1 influenza becoming the next influenza pandemic. The rapid implementation of global and national actions, coordinated by WHO, depended on early disease recognition, high level political support for interventions and transparent communication among the many partners and the public.

## INTRODUCTION

An influenza pandemic (or global epidemic) occurs when a new influenza virus subtype to which no one is immune emerges, is easily spread between humans and is capable of causing severe disease in humans. In the absence of immunity, the new subtype can rapidly spread across the globe, causing worldwide epidemics or 'pandemics' with high numbers of cases and deaths.

The World Health Organization (WHO) in 2005 developed a new WHO Global Influenza Preparedness Plan that redefined the "phases of increasing public health risk associated with the emergence of a new influenza virus subtype that may pose a pandemic threat".

Under the World Health Organization guidelines there are six (6) phases used to identify the WHO Influenza Pandemic Periods.

**Interpandemic Period Phase1:** There are no new influenza virus subtypes detected in humans. An influenza virus subtype that has caused human infection may be present in animals. If present in animals, the risk of human infection or disease is considered to be low.

**Interpandemic Period Phase 2:** There are no new influenza virus subtypes detected in humans. However, a circulating animal influenza virus subtype poses a substantial risk of human disease.

**Pandemic Alert Period Phase 3:** There is human infection with a new subtype, but no humanto-human spread, or at most rare instances of spread to a close contact.

**Pandemic Alert Period Phase 4:** There are small clusters with limited human-to-human transmission but spread is highly localized, suggesting that the virus is not well adapted to humans.

**Pandemic Alert Period Phase 5:** There are larger clusters but human-to-human spread is still localized, suggesting that the virus is becoming increasingly better adapted to humans, but may not yet be fully transmissible (substantial pandemic risk).

**Pandemic Period Phase 6:** This is the Pandemic Phase. There is increased and sustained transmission in the general population.

At the time of revising this plan, November 5, 2007, Jamaica is classified by the WHO to be at the Pandemic Alert Period Phase 3.

This MOH plan is prepared utilizing the recommended actions for national authorities recognizing the need for local and international coordination.

### AIMS AND OBJECTIVES OF THE PLAN

**The aim of this plan** is to provide a detailed guide for the Ministry of Health, Jamaica response to a pandemic influenza threat.

The plan details all procedures, guidelines and actions to be taken within and by the health sector and outlines the steps to be taken by the other Ministries and agencies.

This plan therefore focuses on those persons who will be involved in planning and responding to an influenza pandemic: health planners, public health and clinical health care managers and providers, essential service providers, immigration and customs workers and those involved in the media and communications. As such, it is intended to provide national guidance for key stakeholders in developing and operationalising responses across the public and private sectors at all levels to ensure that Jamaica is optimally prepared and has the capacity to respond to a pandemic threat.

The Ministry of Health Influenza Pandemic Preparedness and Response Plan – November 2007 is to be used at all times during the phases of the pandemic, from preparedness to response. Adequate preparedness is critical to an efficient and effective response to a pandemic event.

There are actions that are necessary at all phases in the plan, which are as outlined in the revised World Health Organization Influenza Pandemic Preparedness Plan 2005.

The declaration of any global Phase by the WHO requires simultaneous declaration of the same phase by the Ministry of Health and the implementation of the relevant section(s) of the plan.

Assessment of risk is therefore to be performed on an on-going basis and will guide the priority actions and the determination of the national subdivision of the plan by the Ministry of Health.

#### The main objectives of this plan are to detail all necessary actions to:

- 1. Ensure adequate surveillance is in place for early detection of an emerging threat and define the epidemiology of the situation on an on-going basis
- 2. Adequately prepare the health sector and guide other sectors to enable smooth and timely implementation of the specific activities required in all phases of pandemic planning, preparedness and response
- 3. Strengthen local laboratory capacity and international links for early detection of the new virus and notification of the response
- 4. Delay entry of the pandemic virus into the country
- 5. Limit pandemic spread through implementation of containment measures
- 6. Limit morbidity and mortality arising from the infection with the pandemic strain of the virus
- 7. Provide the public, health care workers, other Ministries and agencies, the media and other service providers with accurate information at all stages
- 8. Reduce the impact on the health system and the country through early identification and deployment of additional resources required, and
- 9. Implement sound public health and social measures aimed at slowing the spread of the virus.

#### AUTHORITY

The plan is the authoritative guide for the health sector encompassing the actions, required to effectively and efficiently prepare for, prevent and control the medical and health aspects of an Influenza Pandemic.

The Ministry of Health is the lead agency in these efforts.

All other Ministries and agencies, involved in the prevention and control of Pandemic Influenza must be guided by the MOH and work in close collaboration with the MOH.

Collaboration with the Ministry of Agriculture is vital, as the most likely cause of an Influenza Pandemic is an Avian Influenza virus that has crossed the species barrier and is rapidly transmissible from human to human.

Inter-sectoral planning is of paramount importance and will involve coordination of the efforts of other Government Ministries and agencies, such as agriculture and lands, transport, trade, labour, defense and education, as well as partners in the private sector, including industry and non-governmental organizations.

The MOH will advise the ODPEM and National Disaster Committee and Executive, as required in the National Disaster Plan.

ODPEM will coordinate the multi-sectoral response as detailed in the National Disaster Plan.

### ACTIVATION

Sections of the Plan will be used as an operational guide for the actions of the health sector on an on-going basis as dictated by the Phase declared by the WHO.

The relevant section(s) of the response plan will be activated when:

- 1. The World Health Organization has declared a pandemic: Global Phase 6
- 2. The World Health Organization or Ministry of Health has declared that a response is required during the Pandemic Alert period: Phases 3 5, which necessitates on-going coordination of the activities of the health sector or multi-sectoral activities.
- 3. The MOH has determined that there is an imminent epidemic or pandemic or other threat of an Influenza Pandemic to Jamaica.

The Plan will be activated by the Chief Medical Officer (CMO) or the Senior Medical Officer (Health)/ Director, EDMSSB, after consultation with the Permanent Secretary and Minister of Health.

Declaration of activation of the plan at the Phase 6 level will trigger the full activation of the MOH National Emergency Operations Centre (EOC), for 24-hour operations.

Once Jamaica is unaffected, activation of the plan at Phases 3 – 5, will be at Level 1 – when activities for the response are coordinated by the Director, EDMSSB / Director, MOH NEOC, with assistance from the Manager, MOH NEOC, Directors, HSPI, HPP, DPC, Surveillance Officer, CNO, staff of the MOH EDMSSB and other staff required by the Director, MOH NEOC.

Once Jamaica is affected, activation of the plan at Phases 3 - 5, will be at Level 2 - when the MOH NEOC will be activated with all functional areas staffed, with designated hours of operation.

The National Disaster Executive is to be advised once the decision to activate is taken. All other relevant Ministries / agencies will be notified.

# 1.0 PREVENTION

## (Table (1)

| No. | ACTIONS – PREVENTION                                | Person(s) Responsible       |
|-----|---|-----------------------------|
| 1   | Inform the public                                   | Directors, Information and  |
|     | - Develop and implement comprehensive public        | Communication (IC) and      |
|     | education and awareness programme                   | Health Promotion and        |
|     | - Establish and maintain Hotline                    | Education (HPE) / Regional  |
|     | - Establish and maintain MOH website and links to   | Health Promotion Officers   |
|     | other Government and critical sector websites       | (RHPO) / Parish Health      |
|     |   | Education Officers (HEO)    |
| 2   | Educate / Update / Train health care workers        | Directors, Health Promotion |
|     | - Influenza Pandemic                                | and Protection (HPP),       |
|     | - Avian Influenza                                   | Disease Prevention and      |
|     | - Infection Control procedures                      | Control (DPC), Health       |
|     |   | Services Planning and       |
|     |   | Integration (HSPI), EDMSS   |
|     |   | and HPE / RTD / MO(H)       |
| 3   | Educate / update and provide guidance for key       | CMO, Directors, EDMSSB,     |
| 3   | Ministries and agencies, e.g. Ministries of         | VPH, HPP, ODPEM             |
|     | Agriculture, Foreign Affairs and Foreign Trade,     |                             |
|     | Tourism and Industry, Commerce, National            |                             |
|     | Security and Labour and Social Security             |                             |
|     | - Implement MOA and MOH plans and guidelines        |                             |
|     | - Limit / reduce travel, e.g. visas and permits -   |                             |
|     | affected and designated areas                       |                             |
| 4   | Educate / update identified sectors - poultry, port | Directors, VPH, HPP, DPC,   |
|     | authorities, airline and shipping industries        | EDMSSB, HPE and             |
|     | - Port health / Quarantine measures                 | Environmental Health (EH)   |
|     |   | / RTD / MO(H)               |
| 5   | Develop and implement protocols for the handling    | Directors, VPH, DPC, EH     |
|     | of (potentially) contaminated material (See         | and National Public Health  |
|     | Appendix 1)   | Laboratory (NPHL)           |
| 6   | Monitor the agriculture sector, travel industry, in | Directors, VPH, HPP,        |
|     | particular the airline and shipping industries and  | EDMSSB, RTD, MOs(H)         |
|     | tourism sector, and the trade sector                | and EH                      |
| 7   | Prepare Order(s) / Ensure relevant legislation for  | СМО                         |
|     | Quarantine and Public Health measures               |                             |

## II. MITIGATION

These actions are developed to reduce the impact of the organism or disease by providing protection (immunity) using vaccines or prophylaxis, as recommended and available.

| Table | ladie (2)  |   |  |  |
|-------|--|---|--|--|
| No.   | ACTIONS – MITIGATION   | Person(s) Responsible   |  |  |
| 1     | Monitor vaccine / prophylaxis development                                      | Directors, HPP, Family<br>Health (FH) and Standards<br>and Regulations (SR) |  |  |
| 2     | Develop policy for vaccine use, including priorities for use (See Appendix II) | Directors, DPC and FH   |  |  |
| 3     | Implement immunization programme, as determined according to priority list     | Directors, DPC and FH   |  |  |

Table (2)

## III. PREPAREDNESS

All actions are to be taken before the first suspect, probable or confirmed case is reported in Jamaica.

However, preparedness actions are to continue throughout the health sector, even after cases are reported, in areas that are not actively responding or treating cases.

| Table (4) | Та | ble | (4) |  |
|-----------|----|-----|-----|--|
|-----------|----|-----|-----|--|

| -   |  |                            |  |  |
|-----|--|----------------------------|--|--|
| No. | ACTIONS – PREPAREDNESS                                   | Person(s) Responsible      |  |  |
|     | - For Surveillance                                       |                            |  |  |
| 1   | Include Avian Influenza and Pandemic Influenza in        | СМО                        |  |  |
|     | Class 1 notifiable disease list                          |                            |  |  |
| 2   | Strengthen surveillance system                           | Chief Epidemiologist (CE), |  |  |
|     | - Develop and implement new measures, as                 | Directors, HP&P, DPC and   |  |  |
|     | determined (See Appendix III)                            | NPHL / UWI, Microbiology   |  |  |
| 3   | Develop case definition and other diagnostic criteria    | CE, Directors, HPP and     |  |  |
|     | (See Appendix IV)  | HSPI / Director, Medical   |  |  |
|     |  | Services, UHWI / SMO -     |  |  |
|     |  | NCH                        |  |  |
|     | <ul> <li>Preparedness of the Health Sector</li> </ul>    |                            |  |  |
| 4   | Conduct daily literature review and distribute to        | MO(H) Surveillance / Chief |  |  |
|     | senior and other staff, as identified                    | Nursing Officer (CNO)      |  |  |
| 5   | Develop and distribute patient management                | Directors, DPC, HSPI and   |  |  |
|     | protocols, including quarantine and isolation            | SR / Director, Medical     |  |  |
|     | procedures (See Appendix V)                              | Services, UHWI / SMO –     |  |  |
|     |  | NCH                        |  |  |
| 6   | Identify and establish special screening, triage,        | Directors, HSPI and        |  |  |
|     | quarantine and isolation facilities in health facilities | EDMSS, CNO / RTD /         |  |  |
|     | (See Appendix VI)  | MO(H), Parish Manager /    |  |  |
|     |  | SMO                        |  |  |

| <ul> <li>facilities (possibly quarantine and isolation areas) at<br/>the ports and other locations (See Appendix VII)</li> <li>Review and develop Infection Control protocols and<br/>procedures for health care settings (See Infection<br/>Control Manual and Appendix VIII).</li> <li>Establish / maintain Infection Control focal point in<br/>all health facilities</li> <li>Ensure provision and use of personal protective<br/>equipment and appropriate guidelines for health<br/>care workers (See Infection Control Manual)</li> <li>Determine endemic and epidemic levels for<br/>Jamaica</li> <li>Develop laboratory protocols and procedures [and<br/>upgrade facility (ies)] (See Appendix XI)</li> <li>Develop post-mortem procedures and determine<br/>morgue capacity at each facility [and identify<br/>alternate facilities] (See Appendix XI)</li> <li>Develop and distribute technical materials to health<br/>care workers on Avian and Pandemic Influenza, the<br/>management of travellers (Appendix XI), influenza<br/>exposure and supply health facilities, according to<br/>priority list</li> <li>Determine staffing needs and ensure preparation of<br/>rosters for priority services</li> <li>Determine staffing needs and ensure preparation of<br/>rosters for priority services</li> <li>Determine staffing needs and supplies, etc. for health<br/>and EM / RTD / MO(H)</li> <li>Develop policy and guidelines for the management<br/>furniture, reagents and supplies, etc. for health and<br/>ther identified sectors</li> <li>Procure and distribute pharmaceuticals, equipment,<br/>furniture, reagents and supplies, etc. for health and<br/>other identified sectors</li> <li>Develop policy and guidelines for the management<br/>of exposure and illness of health care and other<br/>sector workers, such as agriculture (See Appendix<br/>XIII)</li> <li>Develop and maintain stockpile of pharmaceuticals,<br/>equipment, supplies, sundries and other<br/>emergency materials for the response</li> </ul> | No. | ACTIONS – PREPAREDNESS   | Person(s) Responsible   |
|--|-----|--|---|
| <ul> <li>Review and develop Infection Control protocols and procedures for health care settings (See Infection Control Manual) and Appendix VIII).         <ul> <li>Establish / maintain Infection Control focal point in all health facilities</li> <li>Ensure provision and use of personal protective equipment and appropriate guidelines for health care workers (See Infection Control Manual)</li> </ul> </li> <li>Determine endemic and epidemic levels for Jamaica</li> <li>Develop laboratory protocols and procedures [and transportation protocols (See Appendix X)</li> <li>Develop post-mortem procedures and determine morgue capacity at each facility [and identify alternate facilities] (See Appendix XI)</li> <li>Develop post-mortem procedures and determine morgue capacity at each facility [and identify alternate facilities] (See Appendix XI)</li> <li>Develop and distribute technical materials to health care workers on Avia and Pandemic Influenza, the management of travellers (Appendix XII), influenza exposure and suspect and probable cases</li> <li>Equip and supply health facilities, according to priority list</li> <li>Determine staffing needs and ensure preparation of rosters for priority services</li> <li>Determine staffing needs and ensure preparation of rosters for priority services</li> <li>Procure and distribute pharmaceuticals, equipment, furniture, reagents and supplies, etc. for health and other identified sectors</li> <li>Procure and distribute pharmaceuticals, equipment, furniture, reagents and supplies, sundries and other emergency materials for the response</li> </ul>  | 7   | facilities (possibly quarantine and isolation areas) at  | Directors, EDMSS, HPP   |
| 9         Determine endemic and epidemic levels for<br>Jamaica         CMO, CE, Director, HPF<br>Jamaica           10         Develop laboratory protocols and procedures [and<br>upgrade facility (ies)] (See Appendix IX)<br>- Develop sample collection, handling and<br>transportation protocols (See Appendix X)         Director, NPHL, HSPI,<br>EDMSS and [He<br>Facilities Maintenance<br>(HFMU)] / RTD, [RI<br>MO(H), [Parish Manage]           11         Develop post-mortem procedures and determine<br>morgue capacity at each facility [and identify<br>alternate facilities] (See Appendix X1)         Directors, HSPI, NPHL<br>EDMSS / RTD / MC<br>[Parish Manager] / S<br>[CEO]           12         Develop and distribute technical materials to health<br>care workers on Avian and Pandemic Influenza, the<br>management of travellers ( Appendix XII), influenza<br>exposure and suppect and probable cases         Directors, HSPI, HPP<br>EDMSS, CNO, MC<br>Surveillance           13         Equip and supply health facilities, according to<br>priority list         Directors, HSPI, EDMS<br>HSS&M. RD, RTD , MC<br>Parish Manager           14         Train / update health care workers at all levels         Directors, HSPI, HSSM<br>RTD / MO(H)           15         Determine staffing needs and ensure preparation of<br>rosters for priority services         Directors, HSPI, HSSM<br>EH, /CNO, RTD , MO(<br>SMO & Matron           16         Procure and distribute pharmaceuticals, equipment,<br>furniture, reagents and supplies, etc. for health and<br>other identified sectors         Directors, HSPI, VPH ,<br>and DP&C           17         Develop policy and guidelines of health care and other<br>sector workers, such as agriculture (See Appendix<br>XIII)  | 8   | <ul> <li>Review and develop Infection Control protocols and procedures for health care settings (See Infection Control Manual and Appendix VIII).</li> <li>Establish / maintain Infection Control focal point in all health facilities</li> <li>Ensure provision and use of personal protective equipment and appropriate guidelines for health</li> </ul> | Services Support and<br>Monitoring (HSSM), DPC<br>and SR, CNO / RTD /   |
| upgrade facility (ies)] (See Appendix IX)<br>- Develop sample collection, handling and<br>transportation protocols (See Appendix X)EDMSS and [He<br>Facilities Maintenance<br>(HFMU)] / RTD, [RU<br>MO(H), [Parish Manage11Develop post-mortem procedures and determine<br>morgue capacity at each facility [and identify<br>alternate facilities] (See Appendix XI )Directors, HSPI, NPHL<br>EDMSS / RTD / MC<br>[Parish Manager] / S<br>[CEO]12Develop and distribute technical materials to health<br>care workers on Avian and Pandemic Influenza, the<br>management of travellers (Appendix XII), influenza<br>exposure and suspect and probable casesDirectors, HSPI, HPP<br>EDMSS, CNO, MC<br>Surveillance13Equip and supply health facilities, according to<br>priority listDirectors, HSPI, EDMS<br>BNS&M. RD, RTD , MC<br>Parish Manager14Train / update health care workers at all levelsDirectors, HSPI, HSSM<br>HSS&M. RD, RTD , MO(H)15Determine staffing needs and ensure preparation of<br>rosters for priority servicesDirectors, HSPI, HSSM<br>BH, CNO, RTD , MO(H)16Procure and distribute pharmaceuticals, equipment,<br>furniture, reagents and supplies, etc. for health and<br>other identified sectorsDirectors, HSPI, EDM<br>SR, HPP & HSS&M.<br>RTD, MO(H) & Pa<br>Manager17Develop policy and guidelines for the management<br>of exposure and illness of health care and other<br>sector workers, such as agriculture (See Appendix<br>XIII)Director, EDMSS, SR<br>HCL / RD, RTD / MO(H)18Develop and maintain stockpile of pharmaceuticals,<br>equipment,<br>supplies, sundries and other<br>emergency materials for the responseDirector, EDMSS, SR  | 9   | Determine endemic and epidemic levels for  | CMO, CE, Director, HPP  |
| morguecapacity at each facility [and identify<br>alternate facilities] (See Appendix XI )EDMSS / RTD / MC<br>[Parish Manager] / S<br>[CEO]12Develop and distribute technical materials to health<br>care workers on Avian and Pandemic Influenza, the<br>management of travellers (Appendix XII), influenza<br>exposure and suspect and probable casesDirectors, HSPI, HPP<br>EDMSS, CNO, MC<br>Surveillance13Equip and supply health facilities, according to<br>priority listDirectors, HSPI, EDMS<br>HSS&M. RD, RTD, MC<br>Parish Manager14Train / update health care workers at all levelsDirectors, HSPI, EDMS<br>RTD / MC(H)15Determine staffing needs and ensure preparation of<br>rosters for priority servicesDirectors, HSPI, HSSM<br>BC, HPE and EDMS<br>RTD / MO(H)16Procure and distribute pharmaceuticals, equipment,<br>furniture, reagents and supplies, etc. for health and<br>other identified sectorsDirectors, HSPI, EDM<br>SR, HPP & HSS&M.<br>RTD, MO(H) & Pa<br>Manager17Develop policy and guidelines for the management<br>of exposure and illness of health care and other<br>sector workers, such as agriculture (See Appendix<br>XIII)Director, EDMSS, SR<br>HCL / RD, RTD / MO(H)18Develop and maintain stockpile of pharmaceuticals,<br>equipment, supplies, sundries and other<br>emergency materials for the responseDirector, EDMSS, SR   |     | upgrade facility (ies)] (See Appendix IX)<br>- Develop sample collection, handling and   | Director, NPHL, HSPI, SR,<br>EDMSS and [Health<br>Facilities Maintenance Unit<br>(HFMU)] / RTD, [RD] /<br>MO(H), [Parish Manager] |
| care workers on Avian and Pandemic Influenza, the<br>management of travellers ( Appendix XII), influenza<br>exposure and suspect and probable casesEDMSS, CNO, MC<br>Surveillance13Equip and supply health facilities, according to<br>priority listDirectors, HSPI, EDMS<br>HSS&M. RD, RTD, MC<br>Parish Manager14Train / update health care workers at all levelsDirectors, HSPI, H<br>DPC, HPE and EDMS<br>RTD / MO(H)15Determine staffing needs and ensure preparation of<br>rosters for priority servicesDirectors, HSPI, HSSM<br>EH, /CNO, RTD , MO<br>SMO & Matron16Procure and distribute pharmaceuticals, equipment,<br>furniture, reagents and supplies, etc. for health and<br>other identified sectorsDirectors, HSPI, EDM<br>SR, HPP & HSS&M.<br>RTD, MO(H) & Pa<br>  | 11  | morgue capacity at each facility [and identify   | Directors, HSPI, NPHL and<br>EDMSS / RTD / MO(H),<br>[Parish Manager] / SMO,<br>[CEO]   |
| priority listHSS&M. RD, RTD , MC<br>Parish Manager14Train / update health care workers at all levelsDirectors, HSPI, H<br>DPC, HPE and EDMS<br>RTD / MO(H)15Determine staffing needs and ensure preparation of<br>rosters for priority servicesDirectors, HSPI, HSSM<br>EH, /CNO, RTD , MO(<br>SMO & Matron16Procure and distribute pharmaceuticals, equipment,<br>furniture, reagents and supplies, etc. for health and<br>other identified sectorsDirectors, HSPI, EDM<br>SR, HPP & HSS&M.<br>   | 12  | care workers on Avian and Pandemic Influenza, the management of travellers (Appendix XII), influenza   |   |
| <ul> <li>14 Train / update health care workers at all levels</li> <li>Directors, HSPI, H<br/>DPC, HPE and EDMS<br/>RTD / MO(H)</li> <li>15 Determine staffing needs and ensure preparation of<br/>rosters for priority services</li> <li>16 Procure and distribute pharmaceuticals, equipment,<br/>furniture, reagents and supplies, etc. for health and<br/>other identified sectors</li> <li>17 Develop policy and guidelines for the management<br/>of exposure and illness of health care and other<br/>sector workers, such as agriculture (See Appendix<br/>XIII)</li> <li>18 Develop and maintain stockpile of pharmaceuticals,<br/>equipment, supplies, sundries and other<br/>emergency materials for the response</li> </ul>   | 13  | Equip and supply health facilities, according to   | Directors, HSPI, EDMSS &<br>HSS&M. RD, RTD , MO(H),<br>Parish Manager   |
| rosters for priority servicesEH, /CNO, RTD , MO(<br>SMO & Matron16Procure and distribute pharmaceuticals, equipment,<br>furniture, reagents and supplies, etc. for health and<br>other identified sectorsDirectors, HSPI, EDN<br>SR, HPP & HSS&M.<br>RTD, MO(H) & Pa<br>Manager17Develop policy and guidelines for the management<br>of exposure and illness of health care and other<br>sector workers, such as agriculture (See Appendix<br>XIII)Directors, HSPI, VPH ,<br>and DP&C18Develop and maintain stockpile of pharmaceuticals,<br>equipment, supplies, sundries and other<br>emergency materials for the responseDirector, EDMSS, SR<br>HCL / RD, RTD / MO(H)   | 14  | Train / update health care workers at all levels   | DPC, HPE and EDMSS /  |
| <ul> <li>Procure and distribute pharmaceuticals, equipment, furniture, reagents and supplies, etc. for health and other identified sectors</li> <li>Develop policy and guidelines for the management of exposure and illness of health care and other sector workers, such as agriculture (See Appendix XIII)</li> <li>Develop and maintain stockpile of pharmaceuticals, equipment, supplies, sundries and other emergency materials for the response</li> </ul>  | 15  |  | Directors, HSPI, HSSM and<br>EH, /CNO, RTD, MO(H),<br>SMO & Matron  |
| of exposure and illness of health care and other sector workers, such as agriculture (See Appendix XIII)       and DP&C         18       Develop and maintain stockpile of pharmaceuticals, equipment, supplies, sundries and other emergency materials for the response       Director, EDMSS, SR HCL / RD, RTD / MO(H)   | 16  | furniture, reagents and supplies, etc. for health and  | Directors, HSPI, EDMSS,<br>SR, HPP & HSS&M. RD,<br>RTD, MO(H) & Parish  |
| equipment, supplies, sundries and other HCL / RD, RTD / MO(H) emergency materials for the response   | 17  | of exposure and illness of health care and other sector workers, such as agriculture (See Appendix   | Directors, HSPI, VPH, SR  |
| 19 Prepare needs list and budget Directors, EDMSS & HS   | 18  | equipment, supplies, sundries and other  | Director, EDMSS, SR and<br>HCL / RD, RTD / MO(H)  |
|  | 19  |  | Directors, EDMSS & HSPI   |

| No. | ACTIONS – PREPAREDNESS  | Person(s) Responsible  |
|-----|---|--|
|     | Preparedness of Other Sectors   |  |
| 20  | Liaise with Heads of key Ministries, agencies and<br>sectors and ensure that recommended measures<br>are implemented<br>- Ministry of Agriculture, poultry sector, Port<br>Authorities, Immigration, travel industry, tourism<br>sector | CMO, Directors HPP,<br>EDMSS, HSPI, VPH,<br>Environmental Health and<br>SR / RTD / MO(H) |
| 21  | Educate / update / train staff of all priority and identified sectors   | Directors, EDMSS, HPP<br>VPH and EH / MO(H)  |
| 22  | Develop and distribute technical materials on the<br>Influenza Pandemic and Avian Influenza, the<br>management of travelers and exposure to the<br>Influenza A virus, to workers in other sectors.                                      | Directors, HSPI, HPP,<br>DP&C and EDMSSB,<br>CNO, MO(H) Surveillance                     |
|     | - Preparedness of The Public  |  |
| 23  | Develop and implement Information and Education policy, programme and plan for all sectors and for all phases of the plan ( see APPENDIX XIV ).   | Directors, IC, HPE and EDMSS   |

## IV. PHASES OF THE RESPONSE PLAN

The phases of the response plan are consistent with those of the WHO.

Each of the six (6) phases has clearly defined overarching priority goals, objectives and actions that are divided into five (5) categories:

- 1. Planning and coordination
- 2. Situation monitoring and assessment
- 3. Prevention and containment (non-pharmaceutical public health interventions, vaccines, antivirals)
- 4. Health system response
- 5. Communications

Each of the six (6) Phases has a comprehensive plan of action written with priorities for the five (5) categories above.

The Phases are detailed in Table 3 below:

| PANDEMIC PERIOD       | enza Pandemic Periods and Pha<br>PANDEMIC PHASE   | ADDITIONAL NATIONAL<br>SUBDIVISION OF<br>PHASES                                    |
|-----------------------|---|--|
| Interpandemic Period  | Phase 1:<br>No new influenza virus<br>subtypes have been detected<br>in human.<br>An influenza virus subtype that<br>has caused human infection<br>may be present in animals.<br>If present in animals, the risk of<br>human infection or disease is<br>considered to be low. | FRASES   |
| Interpandemic Period  | Phase 2:<br>No new influenza virus<br>subtypes have been detected<br>in humans.<br>However, a circulating animal  | Country affected or<br>extensive travel / trade<br>links with affected<br>country. |
|                       | influenza virus subtype poses<br>a substantial risk of human<br>disease.  | Country not affected.  |
| Pandemic Alert Period | Phase 3:<br>Human infection(s) with a new<br>subtype, but no human-to-<br>human spread, or at most rare<br>instances of spread to a close   | Country affected or<br>extensive travel / trade<br>links with affected<br>country. |
|                       | contact   | Country not affected.  |
| Pandemic Alert Period | Phase 4:<br>Small cluster(s) with limited<br>human-to-human transmission<br>but spread is highly localized,<br>suggesting that the virus is not   | Country affected or<br>extensive travel / trade<br>links with affected<br>country. |
|                       | well adapted to humans  | Country not affected.  |

# Table 3: WHO Influenza Pandemic Periods and Phases

| PANDEMIC PERIOD       | PANDEMIC PHASE   | ADDITIONAL NATIONAL<br>SUBDIVISION OF<br>PHASES                                    |
|-----------------------|--|--|
| Pandemic Alert Period | Phase 5:<br>Larger cluster(s) but human-to-<br>human spread still localized,<br>suggesting that the virus is<br>becoming increasingly better | Country affected or<br>extensive travel / trade<br>links with affected<br>country. |
|                       | adapted to humans, but may<br>not yet be fully transmissible<br>(substantial pandemic risk).   | Country not affected.  |
| Pandemic Period       | Phase 6:<br>Pandemic phase:  | Country not yet affected.  |
|                       | Increased and sustained<br>transmission in general<br>population   | Country affected or<br>extensive travel / trade<br>links with affected<br>country. |
|                       |  | Subsided.  |
|                       |  | Next wave.   |
| Post Pandemic Period  | Post Pandemic Period   | Return to Interpandemic period   |

a. The distinction between Phase 1 and Phase 2 is based on the risk of human infection or disease resulting from circulating strains in animals. The distinction would be based on various factors and their relative importance according to current scientific knowledge. Factors may include: pathogenicity in animals and humans; occurrence in domesticated animals and livestock or only in wildlife; whether the virus is enzootic or epizootic, geographically localized or widespread; other information from the viral genome; and / or other scientific information.

١

b. The distinction between Phase 3, Phase 4 and Phase 5 is based on an assessment of the risk of a pandemic. Various factors and their relative importance according to current scientific knowledge may be considered. Factors may include: rate of transmission; geographical location and spread; severity of illness; presence of genes from human strains (if derived from an animal strain); other information from the viral genome; and / or other scientific information.

#### DESIGNATION AND DETERMINATION OF PHASES

**Designation of phases, including decisions on upscaling and downscaling, will be made by the Director-General, WHO.** The designation will be made in harmony with existing regulations governing human disease reporting and control (e.g. the International Health Regulations), and in consultation with other organizations and institutions, as necessary.

The determination of the national subdivision of phases will be made by the CMO, in consultation with the Chief Epidemiologist and other technical specialists in the MOH, PAHO and WHO.

Once the declaration of a Phase is made by the WHO, the section of the plan for that Phase will become operational and all relevant persons will be notified, through the use of the Call-Out List.

All actions are to be implemented with urgency and as a priority for the health sector and other relevant sectors.

All efforts are to be made to ensure that actions from the previous Phases are completed, as these are critical to the implementation of the current Phase.

#### Steps To Be Taken:

#### To Determine the National Subdivision of Phases, and To Operationalise The Plan

- 1. Once the WHO designates a Phase, the CMO will consult with the MOH Technical Advisory Group and review available data and information. The MOH Technical Advisory Group will meet with all other relevant Committees and individuals, such as the PWR to ensure that there is full collaboration in decision-making.
- 2. Once determination is made, the CMO will advise the HMH, PS and Director, EDMSSB.
- 3. The Director, EDMSSB will immediately operationalise the plan for the Phase, convene a meeting of the MOH National Influenza Pandemic Preparedness (NIPP) Committee and brief the Committee on the Phase and national subdivision and actions to be taken.
- 4. Advisories will be immediately prepared and forwarded to the relevant authorities, the health sector and other involved sectors.
- 5. All health sectors (Regional, Parish, institution and community level) plans will be activated once the MOH's plan is activated.

## V. RESPONSE PLAN

The level of response will be consistent with those stated in this Plan and the National Plan.

- 1. The response will be initiated by the MOH, in accordance with the guidelines of this Plan, once a notification is received of a suspect or probable case of Avian Influenza.
- 2. All other actions at national, regional, parish, institution and community level for the health sector will be guided by this Plan.
- 3. Once activation of this Plan takes place, all actions of the health sector will be directed and controlled by this Plan and subsequent national level decisions by the MOH Disaster Executive and Emergency Operations Centre.
- 4. All health sector Regional, Parish, institution and community level Plans will be activated once the MOH plan is activated.

### Field Notification and Initial Patient Management Procedure:

Avian Influenza is a Class 1 notifiable disease and must be notified IMMEDIATELY on suspicion and within 24-hrs of the diagnosis.

It is the duty of the consultant physician responsible for the case, to notify the hospital SMO and the Medical Officer (Health) and / or National Surveillance Unit, IMMEDIATELY on suspicion.

The hospital SMO will IMMEDIATELY notify the CEO, Matron, MO(H) and the Director, HSPI who will notify the CMO and Director, EDMSSB.

On receiving the notification of a suspected case of avian influenza or an influenza outbreak, it is the responsibility of the MO(H) of the parish to IMMEDIATELY notify the Regional Technical Director and the Director, HP&P who will IMMEDIATELY notify the CMO and Director, EDMSSB.

The MO(H) will also notify the SMO – parish hospital, if the case was not notified by the hospital.

At the ports, it is the duty of the Quarantine Officer to IMMEDIATELY notify the MO(H) and liaise with the Senior Nurse on duty. The MO(H) will initiate the notification procedure, as above.

All measures for patient management, quarantine and / or isolation MUST be IMMEDIATELY taken to minimize disease transmission.

All other notification procedures within regions, parishes and institutions will be initiated, as planned.

### RESPONSE BY PHASE

This section outlines the actions to be taken at each phase of the pandemic.

Though actions for the Plan are listed sequentially, it is intended that they will be carried out simultaneously. Hence the need for early notification and call-out of the Response teams at all levels.

## 1. INTERPANDEMIC PERIOD: PHASE 1

#### No new influenza virus subtypes have been detected in humans.

An influenza virus subtype that has caused human infection or

disease may or may not be present in animals. If present in animals, the risk of human infection or disease is considered to be low.

**Goal:** To strengthen influenza pandemic preparedness at all levels and enable the smooth and timely implementation of the specific activities required in the various phases of pandemic planning.

**Rationale:** It is likely that influenza subtypes that have caused human infection and / or disease will always be present in wild birds or other animal species. Lack of recognised animal or human infections does not mean that no action is needed. Preparedness requires planning and action in advance.

| Cate | gory: Planning and Coordination  |   |  |
|------|--|---|--|
| Obje | ctives:  |   |  |
| 1.   | 1. To develop and maintain national influenza pandemic contingency plans which are consistent with international plans                 |   |  |
| 2    | . To promote national capacity to respond to early rep   | ports of new influenza virus strains                            |  |
| 3    | . To develop effective mechanisms for mobilization a   | and rapid deployment of resources to                            |  |
|      | areas of need  |   |  |
| 4    | . To develop effective mechanisms for decision-ma  | aking and necessary actions for the                             |  |
|      | national responses.  | -   |  |
|      |  |   |  |
| No.  | Actions  | Responsibility  |  |
| 1    | Establish a MOH National Influenza Pandemic<br>Preparedness Committee  | HMH, PS, CMO, Director, EDMSSB                                  |  |
| 2.i  | Convene MOH NIPP Committee meetings and<br>Jamaica NIPP Committee meetings respectively<br>and review status of preparedness and plans | Directors, EDMSSB / ODPEM                                       |  |
| 2.ii | Meet with Ministry of Agriculture Committee to<br>ensure coordination of activities  | Directors, EDMSSB & VPH   |  |
| 3.i  | Develop and update national plans in close collaboration with relevant partners  | CMO, Director, EDMSSB, Director, Disease Prevention and Control |  |
| 3.ii | Develop Regional, Parish and hospital plans  | RD, RTD, MO(H), Parish Manager, SMO, CEO, Matron                |  |
| 4    | Ensure implementation of plans and preparedness activities at all levels of public authorities   | Directors, EDMSSB and ODPEM /<br>RTDs / MOs(H)                  |  |
| 5    | Conduct simulation exercises and drills to test the plans and refine accordingly   | Directors, EDMSSB and ODPEM / RTDs, MOS(H)                      |  |
| 6    | Identify, brief regularly and train key personnel to<br>be mobilized in case of emergence of a new<br>influenza virus strain           | Directors, EDMSSB and ODPEM /<br>RTDs / MOs(H)                  |  |

| 7  | Develop requirements for a national stockpile<br>(antivirals, personal protective equipment,<br>vaccines, laboratory diagnostics, other technical<br>support) for rapid deployment when needed. | NIPP Committee   |
|----|---|--|
| 8  | Consider providing resources and technical assistance during pandemic alert periods to resource-poor countries with foci of influenza activity.   | HMH, PS, CMO and Director<br>EDMSSB                          |
| 9  | Ensure procedures for rapid sharing of specimens<br>or isolates for virus characterization and<br>development of diagnostics and vaccine.   | Chief Epidemiologist (CE),<br>Directors of NPHL and UHWI lab |
| 10 | Develop surge-capacity contingency plans for the<br>internal management of domestic resources and<br>essential workers during a pandemic  | Directors EDMSSB, HSPI.<br>HRM&CS / CNO                      |
| 11 | Establish national guidance to address food safety,<br>safe agricultural practices and other public health<br>issues related to infected animals.   | Directors VPH and EH   |

| Categ | gory: Situation Monitoring and Assessment   |                              |  |
|-------|---|------------------------------|--|
| Objec | ctives:   |                              |  |
|       | 1. To have available up-to-date information on trends in human infection with seasonal strains of influenza   |                              |  |
| 2.    | 2. To be able to detect animal and human infections with new influenza virus strains, identify potential animal sources of human infections and assess the risk of transmission to humana   |                              |  |
| 3.    | to humans<br><b>3.</b> To develop plans for on-going assessment of impact and resource needs during the pandemic period   |                              |  |
| No.   | Actions   | Responsibility               |  |
| 1     | Develop national surveillance systems for the detection and assessment of clusters of influenza-<br>like illness or respiratory deaths, with provision for surge capacity and intersectoral and inter-<br>institutional collaboration |                              |  |
| 2     | Develop or strengthen national systems for<br>surveillance in both humans and animals based on<br>WHO, FAO and OIE guidance   | Director, DPC, Director, VPH |  |

| 3 | Report routine and unusual surveillance findings to relevant national and international authorities  | CMO, CE, Directors, DPC, National<br>Surveillance Unit and VPH,/ RTDs /<br>MOs(H) |
|---|--|---|
| 4 | Characterize and share virus isolates and<br>information on circulating strains with relevant<br>international agencies, such as CDC, WHO, FAO<br>and OIE  | Director, NPHL, Head,<br>Microbiology, UHWI, Director, VPH                        |
| 5 | Assess burden of seasonal influenza to help estimate additional needs during a pandemic  | "<br>Director, DPC  |
| 6 | Develop contingency plan for ongoing monitoring of<br>information, for assessment of impact and resource<br>needs during the pandemic phase (e.g. morbidity,<br>mortality risk groups affected). | Director, DPC, Surveillance Officer   |

| Phase | Phase 1   |  |  |
|-------|---|--|--|
|       | Category: Prevention and Containment  |  |  |
| Objec | tives:  |  |  |
| 1.    | To agree in advance on a range of contair nonpharmaceutical public health actions.  | nment strategies based on  |  |
| 2.    | To develop a strategy regarding stocking of<br>development.   | antivirals and criteria for  |  |
| 3.    | •   | pandemic.  |  |
| 4.    |   |  |  |
|       | vaccines.   |  |  |
| No.   | ACTIONS   | PERSON(S)<br>RESPONSIBLE   |  |
| 1     | Develop national guidelines for use of public health<br>interventions, considering WHO's<br>recommendations – see Appendix XII.   | Directors, EDMSSB, HSPI,<br>S&R, HP&P  |  |
| 2     | Ensure that proposed interventions are discussed<br>with responsible decision-makers in and outside the<br>health section (transport, education, etc.); ensure<br>legal authority for proposed interventions; anticipate<br>and address resource implications for<br>implementation | PS, CMO, Director<br>EDMSSB, Director HP&P,<br>Director of Legal Affairs,<br>Director, ODPEM |  |
| 3     | Conduct/observe table-top exercise and use the results to improve planning.   | Director EDMSSB,<br>Directors, HSPI, VPH and<br>HP&P   |  |
| 4     | Develop a strategy to ensure access to antiviral for national use (e.g. stock piling)   | DFH  |  |
| 5     | Set priorities and criteria for development and use   | DFH  |  |

|    | of antivirals during pandemic alert and pandemic   |                      |
|----|--|----------------------|
|    | periods.   |                      |
| 6  | Consider participation in research projects to   | Chief Epidemiologist |
|    | assess safety and antiviral drug resistance to   |                      |
|    | current drugs and promote development of   |                      |
| 7  | affordable alternatives.   | DEH                  |
| 1  | Using national data on burden of influenza disease, adapt the national vaccination policy to achieve the | DFH                  |
|    | targets recommended by the World Health  |                      |
|    | Assembly for update of seasonal influenza vaccine.   |                      |
| 8  | Define national objectives for the use of pandemic   | DFH                  |
|    | vaccines; develop preliminary priorities of pandemic   |                      |
|    | vaccine use, based on expected availability  |                      |
| 9  | Explore possible ways to increase access to  | DFH                  |
|    | pandemic vaccines; address regulatory issues and   |                      |
|    | liability.   |                      |
| 10 | Review logistics and operational needs for   | Directors FH, HSPI,  |
| 10 | implementation of pandemic vaccine strategy  |                      |
|    | (vaccine storage, distribution capacity, cold-chain  |                      |
|    | availability, vaccination centers, staffing  |                      |
|    | requirements for vaccine administration).  |                      |

|       | Category: Health System Response                              |                       |  |
|-------|---|-----------------------|--|
| Objec | ctive:  |                       |  |
| T     | o ensure that up-to-date contingency plans and strategies are | in place for pandemic |  |
|       | sponse in the health-care sector.                             |                       |  |
| No.   | ACTIONS   | PERSON(S)             |  |
| 110.  |   | RESPONSIBLE           |  |
| 1     | Determine health system preparedness and address              | CMO, Directors,       |  |
|       | priority deficiencies   | HSPI, EDMSSB &        |  |
|       |   | DPC, RTDs, MOs(H)     |  |
| 1.1   | - Review national level preparedness using WHO                | Directors, EDMSSB,    |  |
| 1.1   | retroit hautena letter propareanees dellig titte              |                       |  |
|       | Checklist for Influenza Pandemic Preparedness Planning        | DPC, HSPI             |  |
| 1.2   | - Identify gaps and prepare priority list of preparedness     |                       |  |
|       | activities  |                       |  |
| 2     | Ensure that authorities, responsibilities and reporting       | "                     |  |
|       | relationships are clearly identified for command and          |                       |  |
|       | control of health systems                                     |                       |  |
| 2.1   | - Review and update organizational structure and              | "                     |  |
|       | command structures  |                       |  |
| 3     | Identify priorities and response strategies for public and    | Directors, EDMSSB,    |  |
| -     | private health care systems for each stage, including         | DPC, HSPI and         |  |
|       | where relevant: triage systems, surge capacity, human         | HSS&M/ RTDs /         |  |
|       | and material resource management                              | MOs(H)                |  |
|       | and material resource management                              |                       |  |

| 4   | Prepare interim: case finding, treatment and management<br>protocols and algorithms: infection control guidelines;<br>guidelines on triaging and surge capacity management<br>and staffing strategies  | CE, Directors DPC,<br>EDMSB & HSPI/<br>SMO-NCH |
|-----|--|--|
| 4.1 | - Review WHO and other relevant reference material.  | "  |
| 4.2 | <ul> <li>Prepare and distribute:</li> <li>a. Case Finding guidelines, including Case Definitions</li> <li>b. Clinical guidelines, protocols and algorithms</li> <li>c. Triage guidelines</li> <li>d. Surge capacity management strategies</li> <li>e. Staffing strategies</li> </ul> | ű  |
| 5   | Ensure implementation of routine laboratory biosafety, safe specimen handling, and hospital infection control procedures   | Directors, HSPI and NPHL and HSSM              |
| 6   | Estimate pharmaceutical and other material supply needs; commence arrangements to secure supply  | Director, S&R                                  |
| 7   | Increase awareness and strengthen training of health care workers on pandemic influenza  | Directors, DPC,<br>EDMSSB & HSPI               |
| 7.1 | - Prepare Fact Sheets  | Dir. HPE, EDMSSB,<br>HSPI                      |
| 8   | Conduct regular simulation exercises of contingency plans, including command and control pathways  | Directors, EDMSSB,<br>HSP&I and DPC            |

|   | Category: Communication – see Appendix XIV   |   |  |
|---|--|---|--|
|   | ctive:   |   |  |
| <ol> <li>To ensure that mechanisms exist for routine and emergency communications<br/>between health authorities, within and between government agencies, with other<br/>organizations likely to be involved in a pandemic response, and with the public.</li> <li>To maintain an appropriate level of awareness among government and other<br/>essential partners.</li> <li>To ensure collaborative working relationships with the media regarding<br/>epidemics, including the roles, responsibilities and operating practices of public<br/>health authorities.</li> </ol> |  |   |  |
| No.   | ACTIONS  | PERSON(S)<br>RESPONSIBLE                        |  |
| 1   | Establish phased national communications strategy for pandemic influenza.  | Directors,<br>EDMSSB, HPE,<br>Communications    |  |
| 2   | Strengthen risk communication related to influenza, taking<br>into consideration existing WHO guidance for outbreak<br>communication and corresponding national contingency<br>plans | Directors,<br>EDMSSB, HPE and<br>Communications |  |
| 3   | Plan and test capacity for meeting expected domestic<br>information demands for diverse audiences, including<br>professional/technical groups, the news media and general<br>public. | Directors,<br>EDMSSB, HPE and<br>Communications |  |

| 4  | Ensure communications infrastructure is adequate for pandemic needs.  | Directors,<br>EDMSSB, HPE and<br>Communications |
|----|---|---|
| 5  | Establish and maintain a web site with relevant information.  | Directors,<br>EDMSSB, HPE and<br>Communications |
| 6  | Establish networks among key response stakeholders, including risk communicators, non-health government departments, and professional and technical groups.                               | Directors,<br>EDMSSB, HPE and<br>Communications |
| 7  | Include risk communicators in senior management groups  | Directors,<br>EDMSSB, HPE and<br>Communications |
| 8  | Familiarize news media with national plans, preparedness activities and decision-making related to seasonal and pandemic influenza.   | Directors,<br>EDMSSB, HPE and<br>Communications |
| 9  | Establish formal communications channels with WHO and<br>other partners for sharing of outbreak information and<br>coordination of communications strategy related to<br>influenza.       | Directors,<br>EDMSSB, HPE and<br>Communications |
| 10 | Develop feedback mechanisms to identify public level of<br>knowledge about pandemic influenza and emerging public<br>concerns. Address rumours proactively, and correct<br>misinformation | Directors,<br>EDMSSB, HPE and<br>Communications |

## **INTERPANDEMIC PERIOD – GLOBAL PHASE 2**

# No new influenza virus subtypes have been detected in humans. However, a circulating animal influenza virus subtype poses a substantial risk of human disease.

**Goal:** To minimize the risk of transmission to humans and detect and report such transmission rapidly if it occurs.

**Rationale:** The presence of animal infection caused by a virus of known human pathogenicity may pose a substantial risk to human health and justify public health measures to protect persons at risk.

## Phase 2 Inter-pandemic Period

| Cate | Category: Planning and Coordination   |  |  |
|------|---|--|--|
| Obje | Objectives:   |  |  |
|      | <ol> <li>To ensure a heightened response capacity to address possible human cases.</li> <li>To coordinate implementation of measures in close collaboration with animal health authorities in order to limit the risks of human infection.</li> </ol> |  |  |
| No.  | ACTIONS   | PERSON(S)<br>RESPONSIBLE   |  |
|      | Affected countries and countries with extensive travel/trade links with affected countries.   |  |  |
| 1    | Activate joint mechanisms for actions with animal health authorities and other relevant organizations.  | Director Vet PH;<br>Director of Vet.<br>Services; Directors<br>EDMSSB, EH &<br>HP&P                    |  |
| 2    | Assess preparedness status and identify immediate actions<br>needed to fill gaps (e.g. with the help of the WHO checklist<br>for influenza pandemic preparedness planning-see WHO<br>website)   | Dir. EDMSSB  |  |
| 3    | Ensure ability to mobilize and rapidly deploy a multisectoral expert response team.   | Directors of<br>EDMSSB, VPH &<br>HPP   |  |
| 4    | Ensure ability to rapidly deploy stockpile resources (national or from global pool) to field locations.   | Director of Family<br>Health; Director of<br>Pharmaceutical<br>Services; Director of<br>EDMSSB         |  |
| 5    | Decide whether to deploy part of the stockpile components according to risk assessment.   | CMO; Director of<br>Family Health;<br>Director of<br>Pharmaceutical<br>Services; Director of<br>EDMSSB |  |
| 6    | Establish a policy on compensation for loss of animals through culling, in order to improve compliance with emergency measures.   | Director of<br>Veterinary Services<br>and Director of VPH.   |  |

# Inter-pandemic Period

| Cate | Category: Situation Monitoring and Assessment  |  |  |
|------|--|--|--|
|      | Objectives:  |  |  |
|      | 1. To identify interspecies transmission at an early stage and transmit this information to PAHO/WHO, CAREC and other appropriate partners.  |  |  |
| 2    | <ul> <li>To provide ongoing risk assessment for transmissi<br/>potential to humans.</li> </ul>   | on of viruses with pandemic                          |  |
| NO.  | ACTIONS  | PERSON(S)<br>RESPONSIBLE                             |  |
|      | Affected countries and countries with extensive travel/trade links with affected countries   |  |  |
| 1    | Implement enhanced animal and human<br>surveillance based on PAHO/WHO, FAO and OIE<br>recommendations; report results daily to the above-<br>mentioned international bodies.   | Directors of EDMSSB;<br>HP&P VPH; & Vet.<br>Services |  |
| 2    | Urgently transmit representative isolates from<br>infected animals to WHO, CDC and OIE designated<br>reference laboratories for confirmation, detailed<br>characterization, development of diagnostic<br>reagents and consideration of suitability for use to<br>develop candidate vaccine viruses/prototype<br>vaccine strains. | Directors of NPHL and Vet<br>Lab.                    |  |
| 3    | Urgently transmit representative isolates from suspected human cases of infection with an animal influenza virus strain to the NPHL.   | Regional Lab. Supervisors                            |  |
| 4    | Conduct field investigations (epidemiological,<br>Laboratory) in affected area to assess spread of the<br>disease in animals and threat to human health.   | Directors of Epidemiology<br>and NPHL                |  |
| 5    | Participate actively in assessment of the risk of transmission (e.g. animal models for pathogenicity testing).   | Directors of Surveillance,<br>VPH and EH             |  |
| 6    | Ensure expertise and capacity for virological<br>surveillance in national laboratories according to<br>standard procedures and using reagents provided<br>by WHO and OIE designated reference laboratories.  | Directors of NPHL and<br>UHWI laboratory             |  |
| 7    | Continue to collect and exchange virus isolates and<br>other scientific information with PAHO, CAREC,<br>CDC.  | Directors of EDMSSB<br>Epidemiology and NPHL         |  |
| 8    | Conduct serological surveillance of farmers (including their families) and animal workers involved in containment of outbreak of animal influenza.   | RTDs   |  |

## Phase 2 Inter-pandemic Period

| Categ | Category – Prevention and Containment   |                          |  |
|-------|---|--------------------------|--|
| -     | Objectives:   |                          |  |
|       | 1. To minimize the risk of human infection from contact with infected animals.  |                          |  |
| 2.    | ,   |                          |  |
| 3.    |   | and thereby minimize the |  |
|       | opportunities for virus re-assortment.  |                          |  |
| NO    | ACTIONS   | PERSON(S)                |  |
|       | Affected countries.   | RESPONSIBLE              |  |
| 1     | Ensure optimal response to the animal outbreak,                                 | Directors, VPH; HP&P FH  |  |
| 1     | including measures to reduce infection risk in those                            | and Vet. Services        |  |
|       | involved in the response (education and training                                |                          |  |
|       | regarding potential threat; correct use of personal                             |                          |  |
|       | protective equipment; deployment of antivirals if risk                          |                          |  |
|       | assessment indicates).  |                          |  |
| 2     | Recommend measures to reduce human contact                                      | Directors, HP&P and VPH  |  |
|       | with potentially infected animals (e.g. advice for                              |                          |  |
|       | travellers).  |                          |  |
| 3     | Prepare for use of further interventions if human                               | Directors, EDMSSB;       |  |
|       | infection is detected.  | HSP&I and DPC            |  |
| 4     | Update information on available national supplies of                            | Director, FH             |  |
| -     | antiviral.  |                          |  |
| 5     | Update recommendations for prophylaxis and                                      | Directors, HSP&I and FH  |  |
|       | treatment with antiviral; consider implementation after normal risk assessment. |                          |  |
|       | anei normai nok assessment.   |                          |  |
|       |   |                          |  |
| 6     | Ensure that antivirals component of a national of                               | Directors HSP&I and FH   |  |
|       | global stockpile could be deployed rapidly from a                               |                          |  |
|       | central location to the affected district(s) and that                           |                          |  |
|       | appropriate staff are familiar with guidance fro                                |                          |  |
|       | deployment and use.   |                          |  |
| 7     | Review strategy for the use of interpandemic                                    | Directors, DPC and FH    |  |
|       | vaccines to prevent dual infection with human and                               |                          |  |
|       | animal viruses, and promote their use in defined risk                           |                          |  |
|       | groups.   |                          |  |
|       |   |                          |  |
| 8     | Develop contingency plans for procuring seasonal                                | Director, FH AND         |  |
|       | vaccine (or specific vaccine, if available) and for                             | EDMSSB                   |  |
|       | distribution once available   |                          |  |
|       |   |                          |  |
|       | Unaffected Countries  |                          |  |
| 1     | Establish or enhance mechanisms for exchange of                                 | CE, Director, NPHL, DPC  |  |
|       | epidemiological and virological data, and of infection                          |                          |  |
|       | control expertise/guidance with affected countries.                             |                          |  |

# **Inter Pandemic Period**

| Cate   | gory: Health System Response   |                                       |  |  |  |
|--------|--|---------------------------------------|--|--|--|
|        | ctive:   |                                       |  |  |  |
| 1. Ťo  | 1. To ensure that if human infections occur, they will be quickly recognized and that the  |                                       |  |  |  |
| health | health systems will respond accordingly  |                                       |  |  |  |
| No.    | ACTIONS  | PERSON(S)<br>RESPONSIBLE              |  |  |  |
|        | Affected countries and countries with extensive travel / trade links with affected countries   |                                       |  |  |  |
| 1      | <ul> <li>Alert local health-care providers to:         <ul> <li>Consider new influenza infection in ill patients with epidemiological links to affected animal species</li> <li>Implement infection control measures</li> <li>Report cases immediately to public health authorities</li> </ul> </li> </ul> | Directors, EDMSSB,<br>HSPI, DPC       |  |  |  |
| 1.1    | Provide algorithms to assist in case finding and management  | Chief, Epidemiology, Director, DPC    |  |  |  |
| 2      | Verify availability and distribution procedures for<br>personal protective equipment and antivirals and for<br>vaccine for the protection of persons at occupational<br>risk   | Directors, EDMSSSB,<br>HSPI           |  |  |  |
| 3      | Ensure rapid deployment of diagnostic tests when available   | Directors, EDMSSB, NPHL               |  |  |  |
|        | All countries  |                                       |  |  |  |
| 1      | Alert health system to review preparedness plans<br>and be ready to receive small numbers of patients<br>with new influenza subtype infection requiring<br>isolation and clinical care   | Director, EDMSSB                      |  |  |  |
| 2      | Assess health system capacity to detect and contain outbreaks of human disease in hospital settings  | Directors, EDMSSB and HSPI            |  |  |  |
| 3      | <ul> <li>Alert local health-care providers to:</li> <li>Consider new influenza infection in ill patients with epidemiological links to affected animal species</li> <li>Implement infection control measures</li> <li>Report cases immediately to public health authorities</li> </ul>                     | Directors, EDMSSB,<br>HSPI, DPC       |  |  |  |
| 3.1    | Provide algorithms to assist in case finding and management  | Chief, Epidemiology,<br>Director, DPC |  |  |  |

#### Interpandemic Period

| Cate | Category – Communications – see Appendix XIV  |                            |  |
|------|---|----------------------------|--|
|      | Objectives:   |                            |  |
| 1    | 1. To ensure that appropriate information is shared rapidly among health                      |                            |  |
|      | authorities, other partners and the public.   |                            |  |
| 2    | 2. To ensure that mechanisms exist for coordinating communications with th                    |                            |  |
|      | animal health sector.   |                            |  |
| No.  | ACTIONS   | PERSON(S)                  |  |
|      |   | RESPONSIBLE                |  |
|      | Affected countries and countries with extensive   |                            |  |
|      | travel/trade links with affected countries  | Directore FDMCCD and       |  |
| 1    | Establish rapid communications to answer questions from health care providers and the public. | Directors EDMSSB and HSP&P |  |
| 2    | Communicate information on risk and prevention (risk  |                            |  |
| 2    | of infection; safe food; animal handling) based on  |                            |  |
|      | WHO's recommendations   | Environmental rieatti.     |  |
| 3    | Address possible stigmatization of  | Director HP&P and RTD      |  |
| -    | individuals/populations in contact with the animal  |                            |  |
|      | strain.   |                            |  |
|      |   |                            |  |
|      | All countries   |                            |  |
| 1    | Update national authorities, other partners and   |                            |  |
|      | stakeholders, including at-risk groups and public, with                                       | EDMSSB                     |  |
|      | current information on virus spread and risks to  |                            |  |
|      | humans.   |                            |  |

### PANDEMIC ALERT PERIOD – GLOBAL PHASE 3

# Human infection(s) with a new subtype, but no human-to-human spread, or at most rare instances of spread to a close contact.

**Goal:** To ensure rapid characterization of the new virus subtype and early detection, notification and response to additional cases.

**Rationale:** The occurrence of cases of human disease increases the chance that the virus may adapt or reassort to become transmissible from human to human, especially if coinciding with a seasonal outbreak of influenza.

Measures are needed to detect and prevent spread of disease. Rare instances of transmission to a close contact – for example, in a household or health care setting - may occur, but do not alter the main attribute of this phase, i.e. that the virus is essentially not transmissible from human to human.

| Phas  | Phase 3   |                                       |  |  |
|-------|---|---------------------------------------|--|--|
| Categ | Category: Planning and Coordination   |                                       |  |  |
| Objec | Objectives:   |                                       |  |  |
| 1.    | 1. To ensure that mechanisms exist so that imminent potential human health  |                                       |  |  |
|       | threats can be recognized and dealt with  |                                       |  |  |
|       | To coordinate timely interventions that will reduce the   |                                       |  |  |
| No.   | ACTIONS   | PERSON(S)<br>RESPONSIBLE              |  |  |
|       | Affected countries and countries with extensive travel / trade links with affected countries  |                                       |  |  |
| 1     | Activate national pandemic contingency planning arrangements  | Directors, EDMSSB,<br>HSPI, DPC       |  |  |
| 2     | Implement interventions to reduce disease burden in<br>the initial foci and contain or delay the spread of<br>infection   | Chief, Epidemiology,<br>Director, DPC |  |  |
| 3     | Mobilize national response and provide guidance to<br>relevant authorities in reviewing, updating and<br>implementing contingency plans   | Directors, EDMSSSB,<br>HSPI           |  |  |
| 4     | Brief appropriate officials in all relevant government<br>Ministries, agencies and departments (e.g. health,<br>agriculture, executive, legislative / judicial) at<br>national, regional and parish levels, regarding the<br>status of the incident and the potential need for<br>additional resources, interventions and the use of<br>emergency power<br>- Special briefing for:<br>- Director General, ODPEM<br>- National Disaster Committee /<br>- Executive | HMH, PS, CMO, Director,<br>EDMSSB     |  |  |
| 5     | Provide assistance to regional. Parish, district and local authorities (including private sector essential services) in implementing interventions  | Director, EDMSSB / RTDs<br>/ MOs(H)   |  |  |

# **Pandemic Alert Period**

| Cate | ory: Situation Monitoring and Assessment  |   |  |
|------|---|---|--|
|      | ctives:   |   |  |
|      | <ol> <li>To be able to exclude wider human-to-human transmission, and to detect this as<br/>soon as it occurs.</li> <li>To be able to detect and characterize additional cases (including risk factors for</li> </ol> |   |  |
|      | transmission).  |   |  |
| NO.  | ACTIONS   | PERSON(S)<br>RESPONSIBLE                                  |  |
|      | Affected countries and countries with extensive travel<br>/ trade links with affected countries   |   |  |
| 1    | Report cases on suspicion of the disease (within 24 hours)<br>and report confirmation as soon as possible thereafter to<br>Epidemiology.  | MOs(H); RTDs;<br>Chief of<br>Epidemiology                 |  |
| 2    | Exclude Laboratory accident or intentional release as the cause of the human cases.   | Chief of<br>Epidemiology                                  |  |
| 3    | Determine the Epidemiology of human cases (source of exposure; incubation period; infection of contacts (clinical and sub-clinical); period of communicability).  | Chief of<br>Epidemiology and<br>Director of DPC           |  |
| 4    | Establish national case definition (or review/modify existing definition based on WHO guidance.   | Chief of<br>Epidemiology                                  |  |
| 5    | Asses clinical characteristics of infections in humans and share with relevant international partners.  | CMO and Director EDMSSB                                   |  |
| 6    | Ensure rapid virological characterization of the virus responsible for human infection, in collaboration with WHO collaborating centres.  | Directors of NPHL<br>and UHWI Lab                         |  |
| 7    | Enhance human and animal surveillance, including cluster detection.   | Directors,<br>Surveillance and<br>VPH                     |  |
| 8    | Collaborate with international efforts to assess virus pathogenicity in humans  | Directors, EDMSSB<br>and Chief of<br>Epidemiology         |  |
| 9    | Identify priority geographical areas and risk groups for targeting with preventive measures.  |   |  |
| 10   | Assess effectiveness of treatment protocols and infection control measures and revised if necessary.  | Directors of HSP&I<br>FH and Standards<br>and Regulations |  |
| 11   | Conduct seroprevalence studies in risk groups, and then<br>expand to the general population, to assess<br>prevalence/incidence of infection (symptomatic and<br>asymptomatic),  | Directors, NPHL and<br>UHWI Lab.                          |  |
| 12   | Continue to collect and share virus isolates and other information needed to develop or adjust diagnostic reagents.   | Directors, NPHL and UHWI Lab.                             |  |

| 12.1 | Monitor any emerging antiviral resistance | Directors,          |
|------|---|---------------------|
|      |   | Surveillance and FH |

# **Pandemic Alert Period**

| Categ       | ory: Prevention and Containment   |  |  |  |
|-------------|---|--|--|--|
| Objectives: |   |  |  |  |
| 1.<br>2.    | <ol> <li>To contain or reduce human-to-human virus transmission.</li> <li>To limit morbidity and mortality associated with current human infections.</li> <li>To assess the potential for use of antivirals in current and later phases.</li> </ol>   |  |  |  |
| 4.<br>NO    | to increase readiness for possible pandemic vaccine devel<br>ACTION   | PERSON(S)  |  |  |
|             | Action  | RESPONSIBLE  |  |  |
|             | Countries with case(s)  |  |  |  |
| 1           | Implement appropriate interventions as identified during contingency planning, in consultation with relevant partners.  | Directors of HSP&I<br>and HP&P                               |  |  |
| 2           | Share virus isolates with WHO in a timely fashion to allow<br>for potential pandemic vaccine development and up dating<br>of reagents.  | Directors of NPHL<br>and UHWI Lab.                           |  |  |
| 3           | <ul> <li>If associated with animal outbreak(s); <ol> <li>Consider deploying supplies of antivirals for post exposure (and possibly pre-exposure) prophylaxis of individuals who are most likely to be exposed to the animal virus.</li> </ol> </li> <li>ii. Continue promoting vaccination with seasonal influenza vaccine to limit risk of dual infection in those most likely to be exposed to the animal virus, and potentially decrease concurrent circulation of human strains in the outbreak-affected area.</li> </ul> | Director of Family<br>Health<br>Director of Family<br>Health |  |  |
|             | All Countries   |  |  |  |
| 1           | Assess or reassess the antivirals.  | Director of Family<br>Health                                 |  |  |
| 2           | Review evidence base for effectiveness and safety of<br>antivirals and if necessary reassess and review strategies,<br>guidelines and priorities for use with partner organizations.  |  |  |  |
| 3           | Reassess emergency methods to increase supply of antivirals.  | Director of Family<br>Health                                 |  |  |
| 4           | Review vaccine use strategies with partner organizations  | Director of Family<br>Health                                 |  |  |

| 5 | Resolve liability and other legal issues linked to use of<br>pandemic vaccine for mass or targeted emergency<br>vaccination campaigns, if not yet done. |                  |                           | -      |
|---|---|------------------|---------------------------|--------|
| 6 | Assess inventories of vaccines and other material resources needed to carry out vaccinations e.g needles and syringes.                                  |                  | of                        | Family |
| 7 | Consider supporting development of prototype vaccines   | CMO,<br>Epidemio | Chie <sup>-</sup><br>logy | f of   |

# **Pandemic Alert Period**

| Cate  | Category: Health System Response  |  |  |
|-------|---|--|--|
| Objec | Objectives:   |  |  |
| 1.    | <ol> <li>To prevent nosocomial transmission and laboratory infections.</li> </ol>   |  |  |
| 2.    | To ensure heightened awareness among health-care w  | vorkers regarding the                                      |  |
|       | possibility of cases and / or clusters of cases.  |  |  |
| No.   | ACTIONS   | PERSON(S)<br>RESPONSIBLE                                   |  |
|       | Affected countries and countries with extensive travel<br>/ trade links with affected countries   |  |  |
| 1     | Activate emergency coordinating Committees<br>a. National – MOH Influenza Pandemic Preparedness<br>Committee / National Influenza Pandemic Preparedness<br>Committee<br>b. Regional – MOH Regional IPP Committee          | Director, EDMSSB   |  |
|       | c. Parish – MOH Parish IPP Committee  |  |  |
| 1.1   | a. Convene / Ensure holding of Committees at 1. above   | Directors, EDMSSB<br>, HSPI, DPC / RTDs<br>/ MOs(H)        |  |
| 1.2   | Activate pre-established coordination between health-care<br>sector and relevant partner organizations<br>- National Influenza Pandemic Preparedness<br>Committee<br>- ODPEM<br>- National Disaster Committee / Executive | Director, EDMSSB   |  |
| 2     | Improve access to care and availability of drugs and<br>medical care at no cost to the patient and health-care<br>system, in order to encourage prompt reporting of new<br>cases  | Directors,<br>EDMSSSB, HSPI,<br>Pharmaceutical<br>Services |  |
| 3     | Review contingency plans at all levels, with special attention to surge capacity  | CMO, Director,<br>EDMSSB, CNO /<br>RTDs / MOs(H) /         |  |

|     |   | Hospital SMO   |
|-----|---|--|
| 4   | Test decision making procedures and chains of command   | Director, EDMSSB /   |
| 4   | Test decision making procedures and chains or command   |  |
| 4.4 | - Conduct circulation eventions at national regional  | RTDs / MOs(H)  |
| 4.1 | a. Conduct simulation exercises at national, regional, parish and hospital levels   | Director EDMSSB  |
| 5   | Train health-care workers to detect/identify clusters of cases.   | Directors, EDMSSB<br>& Surveillance  |
| 6   | Ensure implementation of infection control procedures to prevent nosocomial transmission  | Directors HSPI &<br>HSS&M / CNO /<br>RTDs / MOs(H) /<br>Hospital SMOs and<br>Matrons |
| 6.1 | a. Re-distribute infection control manual and guidelines b.<br>Conduct audit and monitoring visits at all Type S, A and B<br>hospitals and special isolation facilities                       | ű  |
| 7   | Ensure compliance with standards for biosafety in laboratories, and for safe specimen handling and shipment   | Director, NPHL /<br>Head, Microbiology,<br>UHWI                                      |
|     | All countries   |  |
| 1   | Provide public and private health-care providers with<br>updated case definitions, protocols and algorithms to<br>assist with case finding, management, infection control<br>and surveillance | CMO/ Directors,<br>EDMSSB, HSPI,<br>DPC / RTDs /<br>MOs(H)                           |
| 1.1 | Distribute material to all hospitals, health centres and other health facilities  | "  |
| 1.2 | Activate linkages with MAJ and NAJ and provide with material for distribution   | Director, DPC, CNO   |
| 1.3 | Revise mailing list for private practitioners in each parish and distribute material  | RTDs / MOs(H)  |
| 2   | Assess and strengthen capability / capacity for implementing infection control procedures for ill patients  | Directors, EDMSSB,<br>HSPI, DPC  |
| 2.1 | Implement infection control consistent with existing WHO guidance   | Directors, DPC and HSPI  |

**Pandemic Alert** 

Category: Communications

| Objectives: |   |  |  |  |  |
|-------------|---|--|--|--|--|
|             | <ol> <li>To communicate transparently with the public regarding possible outbreak<br/>progression and contingencies to be expected.</li> </ol>  |  |  |  |  |
| 2.          | <ol> <li>To ensure rapid sharing of appropriate information among health authorities,<br/>other relevant government departments and other partners, including what is<br/>known and what is unknown.</li> </ol> |  |  |  |  |
| NO          | ACTIONS   | PERSON(S)<br>RESPONSIBLE                                 |  |  |  |
|             | Affected countries—Jamaica affected   |  |  |  |  |
| 1           | Provide regular updates to WHO and other international and domestic partners on the evolving national situation.  | CMO and Director,<br>EDMSSB                              |  |  |  |
|             | All countries   |  |  |  |  |
| 1           | Identify target groups for delivery of key messages;<br>develop appropriate materials, formats and language<br>options.   | Directors,<br>Communications<br>and HP&P                 |  |  |  |
| 2           | Work with partners to ensure consistent messages are delivered.   | Directors,<br>Communications;<br>HP&P and VPH            |  |  |  |
| 3           | Address the issue of stigmatization of individual/families/communities affected by human infection with the animal strain.  | Directors,<br>Communications;<br>HP&P and VPH            |  |  |  |
| 4           | Review and update information materials for news media, general public, health workers and policy makers.   | Directors,<br>EDMSSB,<br>Communications;<br>HP&P and VPH |  |  |  |
| 5           | Review communication systems and facilities to ensure<br>that they are functioning optimally, and that contact lists<br>are up-to-date.   | Directors, EDMSSB<br>and<br>Communications               |  |  |  |

#### PANDEMIC ALERT PERIOD – GLOBAL PHASE 4

# Small cluster(s) with limited human-to-human transmission but spread is highly localized, suggesting that the virus is not well adapted to humans.

**Goal:** To contain the new virus within limited foci or delay spread to gain time to implement preparedness measures, including vaccine development.

**Rationale:** Virus has increased human-to human transmissibility but is not well adapted to humans and remains highly localized, so that its spread may possibly be delayed or contained.

Examples:

- 1. One or more clusters involving a small number of human cases, e.g. a cluster of < 25 cases lasting < 2 weeks.
- 2. Appearance of a small number of human cases in one or several geographically linked areas without a clear history of a non-human source of exposure, for which the most likely explanation is considered to be human-to-human transmission.

#### Phase 4

| Categ | Category: Planning and Coordination   |                           |  |
|-------|---|---------------------------|--|
| -     | Objectives:   |                           |  |
| 1.    | 1. To ensure that systems exist to detect and characterize outbreaks, and asses |                           |  |
|       | the risk of escalation into a pandemic.   |                           |  |
| 2.    | To coordinate the implementation of procedures that v                           | vill delay or contain the |  |
|       | spread of human infection within limited foci.                                  |                           |  |
| NO    | ACTION  | PERSON (S)<br>RESPONSIBLE |  |
|       | Affected countries – Jamaica affected   |                           |  |
| 1     | Ensure highest levels of political commitment for                               | HMH, PS, CMO              |  |
|       | ongoing and potential interventions/ counter-measures.                          |                           |  |
| 2     | Activate procedures to obtain additional resources;                             | PS, CMO, Director of      |  |
|       | consider invoking emergency powers.   | EDMSSB and MOs(H)         |  |
| _     |   |                           |  |
| 3     | Activate overarching national command and control of                            |                           |  |
|       | response activities, either by formal means or de facto                         | EDMSSB / ODPEM            |  |
|       | (close oversight of district and local activities).                             |                           |  |
| 4     | Deploy operational response teams across all relevant                           | Director of EDMSSB        |  |
|       | sectors.  | and RTDs / ODPEM          |  |
|       |   |                           |  |
| 5     | Ensure collaboration with surrounding countries for                             |                           |  |
|       | information-sharing and coordination of emergency                               | EDMSSB                    |  |
|       | responses.  |                           |  |
| 6     | Identify needs for international assistance.                                    | Director EDMSSB           |  |

|   | Unaffected countries – No cases  |  |
|---|--|--|
| 1 | Activate national pandemic contingency planning arrangements.  | Director of EDMSSB                     |
| 2 | Reassess current state of preparedness using Jamaica's check list for influenza pandemic planning and national tools; implement actions required to close priority gaps. | Director of EDMSSB,<br>RTDs and MOs(H) |
| 3 | Identify ability to respond to requests for international assistance.  | Director of EDMSSB                     |

| Categ | ory: Situation Assessment and Monitoring  |   |  |  |
|-------|---|---|--|--|
| Objec | Objectives:   |   |  |  |
|       | . To assess the extent of human-to-human transmission .   |   |  |  |
| 2.    | 2. To detect, notify and characterize additional clusters (including the identification of  |   |  |  |
|       | risk factors and other data concerning transmission as requested by WHO.  |   |  |  |
| 3.    | 3. To assess the threat to human health and the impact of any control measures, and   |   |  |  |
|       | identify resources required for enhanced control.   |   |  |  |
| NO    | ACTIONS   | PERSON(S)<br>RESPONSIBLE                                |  |  |
|       | Affected countries – Jamaica affected   |   |  |  |
| 1     | Describe and (re)assess the epidemiological, virological<br>and clinical features of infection; identify possible<br>source(s).                               | Chief Epidemiologist and<br>Directors, HSP&I and<br>DPC |  |  |
| 2     | Report this information on cases and clusters through<br>appropriate mechanisms, eg international Health<br>Regulations, to WHO and other appropriate bodies. | CMO and Chief<br>Epidemiologist and<br>Director, EDMSSB |  |  |
| 3     | Expand activities already under way in pandemic alert period Phase 1; adjust case definition if necessary.  | CMO, Director of EDMSSB, CE                             |  |  |
| 4     | Assess sustainability of human-to-human transmission  | CE  |  |  |
| 5     | Conduct clinical research to optimize treatment protocols, if resources are available.  | Director of HP&P and<br>Chief Epidemiologist            |  |  |
| 6     | Collect and share strains and information needed to develop or adjust diagnostic reagents and prototype vaccines.   | Directors of HP & P,<br>NPHL and UHWI Lab.<br>CE        |  |  |
| 7     | Forecast likely impact of the spread of infection   | Director, Surveillance                                  |  |  |
| 8     | Attempt to assess the impact of containment measures<br>to allow for adjustment of recommendations; share   | CMO; Chief<br>Epidemiologist and                        |  |  |

|   | findings urgently with the international community.<br>(including WHO) to allow updating of national and<br>international policies. | Director EDMSSB                       |
|---|---|---------------------------------------|
| 9 | Enhance surge capacity for surveillance.  | Directors of HP&P and<br>Surveillance |
|   | Unaffected countries  |                                       |
| 3 | Enhance surveillance, especially in countries with travel/trade links to affected areas.  | Directors of EDMSSB and Surveillance  |

| Cate | ory: Prevention and containment  |                           |  |
|------|--|---------------------------|--|
|      | Objectives:  |                           |  |
| -    | 1. To contain or delay human-to-human virus transmission.  |                           |  |
| 2.   | •  |                           |  |
| 3.   | To assess the potential for wider usage of antivirals in lat   | er phases.                |  |
| 4.   |  |                           |  |
| 5.   | To gain early experience in pandemic vaccine use u   | nder field conditions (if |  |
|      | clinical trial lots are available).  |                           |  |
| NO   | ACTIONS  | PERSON(S)                 |  |
|      |  | RESPONSIBLE               |  |
|      | Countries with cases   |                           |  |
| 1    | Implement appropriate interventions identified during  | Directors of EDMSSB       |  |
|      | contingency planning, and consider any new guidance  | and HSP&I                 |  |
|      | provided by WHO.   |                           |  |
|      |  |                           |  |
| 2    | Evaluate the effectiveness of these measures in  | Directors of EDMSSB       |  |
|      | collaboration with WHO.  | and HSP&I                 |  |
| 3    | Use antivirals for early treatment of cases, and consider  | Directors of FH and       |  |
|      | antiviral prophylaxis for close contacts of cases based  | DPC                       |  |
| 4    | on risk assessment and severity of illness in humans.  | Directory of EUL and      |  |
| 4    | Assess likely effectiveness and feasibility of prophylaxis   | Directors of FH and       |  |
|      | for the purpose of attempting to contain outbreaks.  | DPC                       |  |
|      | Determine target population; if intervention agreed,   |                           |  |
| 5    | implement as an emergency measure; assess impact.<br>Consider deploying prototype pandemic vaccine. if | Director of FH            |  |
| 5    | Consider deploying prototype pandemic vaccine, if available.   |                           |  |
|      | Countries without cases  |                           |  |
| 1    | Assess need to deploy current antiviral stock to   | Director of FH            |  |
|      | local/regional level to facilitate rapid implementation of   |                           |  |
|      | antiviral strategy (if this becomes necessary).  |                           |  |
| 2    | Consider supporting pilot programmes   | Director of Family        |  |
| 2    |  | Health                    |  |
|      |  | Ticalui                   |  |

### **Pandemic Alert Period**

| Cate | gory: Health System Response   |  |  |
|------|--|--|--|
| Obje | ctives:  |  |  |
| 1.   | 1. To prevent nosocomial transmission.   |  |  |
| 2.   | 2. To maintain biosafety.  |  |  |
| 3.   | To ensure capacity is available and used optimally in affect   |  |  |
| No.  | ACTIONS  | PERSON(S)<br>RESPONSIBLE                           |  |
|      | Affected countries – Jamaica affected  |  |  |
| 1    | Update and reinforce messages to local health-care providers to consider influenza infection in ill patients and report findings to public health authorities                  | Directors, EDMSSB,<br>HSPI, DPC                    |  |
| 1.1  | Review WHO declaration and format and prepare new information for distribution   | "  |  |
| 1.2  | Distribute using lists and guidelines as for Phase 3   | "  |  |
| 2    | Update case definition, protocols and algorithms for case-<br>finding, management (antivirals and other required drugs),<br>infection control and surveillance as required.    | Directors, EDMSSB,<br>HSPI and DPC                 |  |
| 3    | Activate contingency plans for response to overload of<br>health facilities with influenza patients, and identify<br>alternative strategies for case isolation and management. | Directors,<br>EDMSSSB, HSPI                        |  |
| 4    | Implement surge capacity arrangements and contingency<br>plans for staff shortages in health-care facilities and in all<br>other key activity sectors.                         | HMH, PS, CMO,<br>Director, EDMSSB                  |  |
| 5    | Re-emphasize infection control measures and issue stockpiles of persona protective equipment.  | Director, EDMSSB /<br>RTDs / MOs(H)                |  |
|      | Unaffected countries – Jamaica not affected  |  |  |
| 1    | Activate contingency planning arrangements.  | Directors, EDMSSB,<br>HSPI, DPC / RTDs /<br>MOs(H) |  |

| Cateo | ory: Communication – see Appendix XIV   |   |  |
|-------|---|---|--|
| Objec |   |   |  |
| 1.    | <ol> <li>To ensure rapid sharing of appropriate information among health authorities,<br/>other relevant government departments and other partners, including what is<br/>known and what is unknown.</li> <li>To prepare the public and partners for a possible rapid progression of events and<br/>possible contingency measures.</li> </ol> |   |  |
| NO    | ACTIONS   | PERSON (S)<br>RESPONSIBLE   |  |
|       | Affected countries – Jamaica affected   |   |  |
| 1     | Reinforce and intensify key messages on prevention of human-to-human spread.  | Directors of HP&P and Communication                               |  |
| 2     | Explain rationale and update public on all aspects of outbreak response and likely next steps.  | Directors of<br>EDMSSB; HP&P<br>and Communication                 |  |
| 3     | Provide instruction in self-protection  | Directors of<br>EDMSSB; HP&P<br>and Communication                 |  |
|       | All countries affected  |   |  |
| 1     | Update national authorities, other partner organizations/stakeholders and the public on the domestic and international epidemiological situation and known disease characteristics.   | Directors of<br>EDMSSB; HP&P<br>Communication and<br>Epidemiology |  |
| 2     | Activate emergency communications plan.   | Directors of<br>EDMSSB; HP&P<br>and Communication                 |  |
| 3     | In conjunction with partner organizations; update communications messages   | Directors of<br>EDMSSB; HP&P<br>and Communication                 |  |
| 4     | Develop general health protection education materials, eg templates, for national and local applications.   | Directors of<br>EDMSSB; HP&P<br>and Communication                 |  |
| 5     | Re-emphasize infection-control measures in the community, health-care settings, and long-term care facilities.  | Directors of<br>EDMSSB; HP&P<br>and Communication                 |  |

#### PANDEMIC ALERT PERIOD – GLOBAL PHASE 5

# Large cluster(s) but human-to-human spread is still localized, suggesting that the virus is becoming increasingly better adapted to humans, but may not yet be fully transmissible (substantial pandemic risk).

**Goal:** To maximize efforts to contain or delay spread, to possibly avert a pandemic and to gain time to implement pandemic response measures.

**Rationale:** Virus is more adapted to humans and therefore more easily transmissible among humans. It spreads in larger clusters, but spread is localized.

This is likely to be the last chance for massive coordinated global intervention, targeted to one or more foci, to delay or contain spread. In view of possible delays in documenting spread of infection during pandemic Phase 4, it is anticipated that there would be a low threshold for progressing to Phase 5.

#### Examples:

- 1. On-going cluster-related transmission, but total number of cases is not rapidly increasing, e.g. a cluster of 25 50 cases and lasting from 2 to 4 weeks.
- 2. On-going transmission, but cases appear to be localized (remote village, university, military base, island).

#### Phase 5

| Cate  | Category: Planning and Coordination   |   |  |  |
|---|---|---|--|--|
| Obje  | Objective:  |   |  |  |
| <ol> <li>To coordinate and ensure maximum efforts to delay or possibly avert a pandemic.</li> </ol> |   |   |  |  |
| NO  | ACTIONS   | PERSON(S)<br>RESPONSIBLE                          |  |  |
|   | Affected countries – Jamaica affected   |   |  |  |
| 1   | As needed, designate special status to affected area in order to facilitate interventions (e.g. state of emergency).  | HMH and CMO                                       |  |  |
| 2   | Assist in the ongoing evaluation of interventions.  | Directors of<br>EDMSSB;<br>Surveillance and<br>FH |  |  |
| 3   | Finalize preparations for imminent pandemic, including activation of internal organizational arrangements (within command-and-control system) and staffing search capacity. | Directors of<br>EDMSSB and HR                     |  |  |

| 4 | Adjust and maximize efforts and resources to reduce | Directors of |
|---|---|--------------|
|   | disease burden and contain or delay the spread of   |              |
|   | infections.   | and FH       |

| Cate | ory: Situation Monitoring and Assessment   |   |
|------|--|---|
|      | ctives:  |   |
|      | To determine pandemic risk and exclude spread to other identify this as soon as it occurs.<br>To determine and monitor public health resources response.   | ·   |
| NO   | ACTIONS  | PERSON(S)<br>RESPONSIBLE                              |
|      | Affected countries – Jamaica affected  |   |
| 1    | Expand and adjust activities in pandemic alert period,<br>Phase 2, to maximum intensity.   | Directors of EDMSSB;<br>HP&P VPH and Vet.<br>Services |
| 2    | Report increased spread through appropriate means,<br>including the revised International Health Regulations,<br>as a public health emergency of international concern<br>(PHEIC)  | CMO and Director of<br>EDMSSB                         |
| 3    | Implement real-time monitoring of essential resources<br>(medical supplies, pharmaceuticals, infrastructure,<br>vaccines, hospital capacity, human resources, etc.).   | Directors of EDMSSB,<br>HSP&I,FH and HR               |
| 4    | Conduct enhanced surveillance for respiratory disease through surveys (telephone of questionnaires).   | CE and Director of<br>Surveillance                    |
| 5    | Adjust forecasts of the likely impact of both infection spread and control measures.   | Director of EDMSSB<br>and CE                          |
| 6    | Assess impact of containment measures to-date in order<br>to allow for readjustment, if necessary; share findings<br>with the international community to allow updating of<br>national and international guidance/recommendations. | CMO, CE and Director of EDMSSB.                       |
| 7    | Monitor the development of antiviral resistance.   | CE and Director of<br>Surveillance                    |
|      | Unaffected countries   |   |
| 1    | Enhance surveillance measures to maximum intensity.  | Director of<br>Surveillance                           |

## **Pandemic Alert**

|     | ctives:   |               |              |  |
|-----|---|---------------|--------------|--|
| 1.  | To make massive efforts to contain or delay human-to-human virus transmission |               |              |  |
|     | and the onset of a pandemic.  |               |              |  |
| 2.  | To limit morbidity and mortality associated with current hum                  | nan infection | s.           |  |
| 3.  | To assess the potential for usage of antivirals in the pander                 | nic period.   |              |  |
| 4.  | To support preparations for deployment of vaccine as supp                     | lies become   | available.   |  |
| 5.  | To gain early experience in pandemic vaccine use unc                          | ler field cor | nditions (if |  |
|     | clinical trial lots are available).   |               |              |  |
| No. | ACTIONS   | PERSON(       | S)           |  |
|     |   | RESPONS       | SIBLE        |  |
|     | Countries with cases  |               |              |  |
| 1   | Implement interventions identified during contingency                         | Directors     | of Family    |  |
|     | planning and new guidance provided by WHO.                                    | Health and    | •            |  |
| 2   | Consider/reconsider use of antivirals for early treatment of                  | Director of   | of Family    |  |
|     | cases (prioritization may need to be changed).                                | Health        | ,<br>,       |  |
| 3   | Assess/reassess efficacy and feasibility of prophylaxis for                   | Director of   | of Family    |  |
|     | the purpose of attempting to contain outbreaks.                               | Health        | J            |  |
|     | Determine target population; if intervention agreed,                          |               |              |  |
|     | implement as an emergency measure; assess impact.                             |               |              |  |
| 4   | Consider deploying prototype pandemic vaccine, if                             | Director of   | of Family    |  |
|     | available.  | Health        | J            |  |
|     | Countries without cases   |               |              |  |
| 1   | Reassess need to deploy current antiviral stock to                            | Director of   | of Family    |  |
| -   | local/regional level to facilitate rapid implementation of                    | Health        | <b>,</b>     |  |
|     | antiviral strategy (if this becomes necessary).                               |               |              |  |
| 2   | Consider results and lessons learned from use in countries                    | Director of   | of Family    |  |
|     | with cases and modify antiviral strategy (if applicable).                     | Health        | J            |  |
| 3   | Not applicable to Jamaica (about vaccine production)                          |               |              |  |
| 4   | Plan for vaccine distribution and accelerate preparations                     | Director of   | of Family    |  |
|     | for mass vaccination campaigns (eg. Education,                                | Health        |              |  |
|     | legal/liability issues) for when pandemic vaccine becomes                     |               |              |  |
|     | available.  |               |              |  |
| 5   | Adjust priority lists of persons to be vaccinated (if                         | Director of   | of Family    |  |
| •   | applicable).  | Health        | <b>,</b>     |  |
|     | If pandemic vaccine has already been developed                                |               |              |  |
| 3   | Activate emergency procedures for rapid licensing and use                     | Directors     | of Family    |  |
| C . | of pandemic vaccines (all countries).   | Health        | and          |  |
|     |   | Standards     |              |  |
|     |   | &Regulatio    | ons          |  |
| 4   | Consider allocating vaccine for population-based                              | Director (    |              |  |
|     | intervention aimed at containing infection within currently                   | Health        | c. i anny    |  |
|     | affected areas.   | . iouiii      |              |  |
| 5   | Consider implementing pandemic vaccine strategy as                            | Director of   | of Family    |  |
| 5   | indicated in pandemic period.   | Health        | c. runny     |  |
|     |   | i iouitii     |              |  |

٦

# **Pandemic Alert Period**

| Categ | Category: Health System Response   |  |  |
|-------|--|--|--|
|       | Objectives:  |  |  |
|       | <ol> <li>To ensure that health systems are ready to increase the response and implement<br/>changes in triage and treatment priorities, and that these actions occur as soon as a<br/>country becomes affected.</li> <li>To prevent nosocomial transmission and maintain biosafety.</li> </ol> |  |  |
| No.   | ACTIONS  |  |  |
| INO.  |  | PERSON(S)<br>RESPONSIBLE                           |  |
|       | Affected countries – Jamaica affected  |  |  |
| 1     | Full mobilization of health services and full implementation of emergency / contingency plans in affected areas, including coordination with other emergency sectors.  | Directors, EDMSSB,<br>HSPI, DPC                    |  |
| 1.1   | Review WHO declaration and format and prepare new information for distribution   | Directors, EDMSSB,<br>HSPI, DPC                    |  |
| 1.2   | Distribute using lists and guidelines as for Phase 3   | Directors, EDMSSB,<br>HSPI, DPC                    |  |
| 2     | Commence triage arrangements and other emergency procedures for efficient use of health-care facilities.   | Directors, EDMSSB,<br>HSPI and DPC                 |  |
| 3     | Fully implement emergency plans for deployment of health-care workers.   | Directors, EDMSSSB,<br>HSPI                        |  |
| 4     | Ensure attention to the health and other needs of persons in quarantine.   | HMH, PS, CMO, Director, EDMSSB                     |  |
| 5     | Arrange for additional human and material resources and<br>alternative means of health-care delivery, based on<br>forecast needs and contingency plans.  | Director, EDMSSB /<br>RTDs / MOs(H)                |  |
| 6     | Implement corpse management procedures (see Appendix XI)   | Director EDMSSB/<br>RTDs/ MOs(H)                   |  |
| 7     | Prepare health-care workers for potential change in policy regarding antivirals for occupational exposures (switch from prophylaxis to early treatment).   | Director Family Health                             |  |
| 4     | Unaffected countries – Jamaica not affected  | 5514005  |  |
| 1     | Activate emergency coordinating Committees for the<br>health system.<br>- National<br>- Regional<br>- Parish<br>- Hospital   | Directors, EDMSSB,<br>HSPI, DPC / RTDs /<br>MOs(H) |  |
| 2     | Provide public and private health care-care providers with<br>updated case definition, protocols and algorithms for case-<br>finding, management, infection control and surveillance.  | Directors, EDMSSB,<br>HSPI, DPC/ RTDs/<br>MOs(H)   |  |
| 3     | Explore ways to provide drugs and medical care free of charge (or covered by insurance) to the patient and the   | Permanent Secretary/<br>CMO/ Directors,            |  |

|   | health care delivery system, to encourage prompt reporting and treatment.   | EDMSSB,HSP&I &<br>HSSM                                 |
|---|---|--|
| 4 | Assess capability / capacity for infection control for ill patients and implement infection control consistent with WHO guidelines. | Directors, EDMSSB,<br>HSPI, DPC/ RTDs/<br>MOs(H)/ SMOs |
| 5 | Review contingency plans relevant to health systems response at all levels, with special attention to surge capacity arrangements.  | Directors, EDMSSB,<br>HSPI, DPC/ RTDs/<br>MOs(H)/ SMOs |
| 6 | Test decision procedures and chains of command, and<br>other pandemic working arrangements to ensure that they<br>are functioning.  | Directors, EDMSSB,<br>HSPI, DPC/ RTDs/<br>MOs(H)/ SMOs |
| 7 | Train health care workers to detect / identify cases and clusters.  | Directors, EDMSSB & Surveillance                       |

# **Pandemic Alert Period**

| Categ | Category: Communications                                    |                         |  |
|-------|---|-------------------------|--|
| Objec | Objectives:   |                         |  |
| 1.    | To prepare the public and other partners for a likely rapid |                         |  |
|       | additional contingency measures, and disruptions to norma   | al life.                |  |
| 2.    | To ensure rapid sharing of appropriate information amo      | ong health authorities, |  |
|       | other relevant government departments and other partne      | ers, including what is  |  |
|       | known and what is unknown.                                  |                         |  |
| No.   | ACTIONS   | PERSON(S)               |  |
|       |   | RESPONSIBLE             |  |
| 1     | Redefine key messages; set responsible public               | Directors of            |  |
|       | expectations; emphasis need to comply with public health    | EDMSSB and              |  |
|       | measures despite their possible limitations.                | Communication           |  |
| 2     | Utilize last "window of opportunity" to refine              | Directors of            |  |
|       | communications strategies and systems in anticipation of    | EDMSSB and              |  |
|       | imminent pandemic.  | Communication           |  |
| 3     | Inform public about interventions that may be modified or   | CMO; Directors of       |  |
|       | implemented during a pandemic, e.g. prioritization of       | EDMSSB and              |  |
|       | health-care services and supplies, travel restrictions,     | Communication           |  |
|       | shortage of basic commodities etc.                          |                         |  |

#### PANDEMIC PERIOD – GLOBAL PHASE 6

#### Pandemic increased and sustained transmission in the general population.

Goal: To minimize the impact of the pandemic.

**Rationale:** Major change in global surveillance and response strategy, since pandemic risk is imminent for all countries. The national response is determined primarily by the disease impact within the country.

The intensity of activities in Jamaica will depend largely on whether there are cases in the country. The eventual appearance of cases in Jamaica is considered virtually inevitable.

If affected, Jamaica should follow the recommendations below. If unaffected, preparations should be made to implement these recommendations rapidly, especially if there is extensive trade/travel links with affected countries.

Phase 6

| Categ | Category: Planning and Coordination  |                           |  |
|-------|--|---------------------------|--|
| Objec | Objectives:  |                           |  |
| 1.    | . To provide leadership and coordination of multi-sectoral resources that will:                          |                           |  |
|       | minimize morbidity and mortality; preserve health-ca   | are system effectiveness; |  |
|       | minimize societal disruption; and minimize the economic  |                           |  |
| 2.    | 2. To ensure rational access to finite national resources, including pharmaceutical                      |                           |  |
|       | supplies and (when available) vaccine.   |                           |  |
|       | 3. To evaluate the effective of specific responses and in  |                           |  |
| 4.    | 4. To establish and maintain trust across all agencies a   | •                         |  |
| _     | the public, through a commitment to transparency and c   |                           |  |
| 5.    | 5. To draw lessons from the ongoing pandemic resp  | oonse in order to improve |  |
|       | responses strategy and inform future planning.   |                           |  |
| No.   | ACTIONS  | PERSON(S)                 |  |
|       | <b>A</b>   | RESPONSIBLE               |  |
|       | Countries not yet affected-Jamaican not yet affected   |                           |  |
| 1.    |  | Directors of ODPEM        |  |
| ١.    | Activate crises committee(s) and national command<br>and control of emergency operations (if not already | and EDMSSB                |  |
|       | done.)   |                           |  |
| 2     | Finalize adjustment of official guidelines and   | Directors of ODPEM        |  |
| 2     | recommendations.   | and EDMSSB                |  |
| 3     | Provide guidance to local authorities in all sectors on  |                           |  |
| 5     | implementation and evaluation of proposed  | and EDMSSB                |  |
|       | interventions.   |                           |  |
|       |  |                           |  |

|    | Affected countries- Jamaican affected   |   |
|----|---|---|
| 1. | Implement all relevant elements of national pandemic<br>plan, including coordination of response and<br>implementation of specific interventions. | Directors of EDMSSB<br>VPH and Vet. Medicine              |
| 2  | Assess and publicize the current and cumulative national impact.  | Directors of EDMSSB<br>VPH and Vet. Medicine              |
| 3  | Consider apply emergency powers   | HM of Health and CMO                                      |
|    | Subsided (end of pandemic or between waves)   |   |
| 1  | Determine need for additional resources and powers during subsequent pandemic waves   | CMO; Directors of<br>EDMSSB; FH; VPH and<br>Vet. Medicine |
| 2  | Declare end of emergency command-and-control operations, states of emergency, etc.  | CMO; Directors of<br>ODPEM & EDMSSB                       |
| 3  | Support rebuilding of essential service, including rotating, rest and recuperation for staff  | Directors EDMSSB;<br>HSP&I HP&P                           |
| 4  | Review national plan based on experiences   | Directors EDMSSB;<br>HSP&I HP&P VPH and<br>Vet. Medicine  |
| 5  | Address physiological impacts   | Directors of Mental<br>Health and HP&P                    |
| 6  | Acknowledge contributions of all stakeho9lders (including the public) and essential staff towards fighting the disease                            | CMO; Director<br>EDMSSB; HSP&I<br>HP&P                    |
| 7  | Consider offering assistance to remaining countries with ongoing widespread activity  | CMO; Director, EDMSSB                                     |

| Categ | Category: Situation Monitoring and Assessment  |                                  |  |
|-------|--|----------------------------------|--|
| Objec | tive:  |                                  |  |
|       | 1. To monitor the epidemiological, virological and clinical features, and<br>the course and impact of the pandemic at the national level, in order<br>to forecast trends and optimize the use of finite resources. |                                  |  |
| 2.    | <ol><li>To assess the effectiveness of interventions used to date in order to<br/>guide future actions.</li></ol>  |                                  |  |
| No.   | ACTIONS  | PERSON(S)<br>RESPONSIBLE         |  |
|       | Countries not affected– Jamaica not yet affected   |                                  |  |
| 1     | Continue enhance surveillance measures as for Phase 5 (unaffected country).  | CE & Director of<br>Surveillance |  |

| 2 | Monitor global situation (vaccine/antiviral availability, recommendations for best practices, etc.).  | Director of<br>Family Health                      |
|---|---|---|
| 3 | Estimate the impact of vaccination and antiviral programmes used elsewhere (safety, efficacy and antiviral resistance).   | Directors of<br>Surveillance and<br>Family Health |
|   | Affected countries – Jamaica affected   |   |
| 1 | Monitor geographical spread of disease from point(s) of introduction/first detection.   | CE & Director of<br>Surveillance.                 |
| 2 | Use enhance surveillance and case-management database to identify initial cases/contacts and track initial geographical spread.   | CE & Directors<br>of Surveillance<br>and DPC.     |
| 3 | Monitor for possible changes in epidemiology, clinical presentation and virological features.   | CE & Directors<br>of Surveillance<br>and DPC.     |
| 4 | Monitor and assess national impact (morbidity,<br>mortality, workplace absenteeism, regions affected,<br>risk groups affected, health –care worker<br>availability, essential worker availability, health-<br>care supplies, bed occupancy/availability,<br>admission pressures, use of alternative health<br>facilities, mortuary capacity, etc.).   | Directors of<br>EDMSSB;<br>HSP&I HRM<br>and RTDs. |
| 5 | Assess need for emergency measures, eg<br>emergency burial procedures, use of legal powers<br>to maintain essential services.   | Directors of<br>EDMSSB , Legal<br>Affairs & EH    |
| 6 | If sufficient resources, forecast trends (course of pandemic) and economic impact.  | CE & Director of<br>Surveillance                  |
| 7 | Assess uptake and impact of: treatments and<br>countermeasures, including vaccine/antiviral<br>efficacy and safety and emergence of antiviral<br>resistance; non pharmaceutical interventions: etc.   | Directors of<br>Family Health<br>and DPC          |
| 8 | As disease activity intensifies and becomes more<br>wide spread, adjust surveillance (e.g. Reduce<br>virological surveillance, discontinue case-<br>management database) and adjust case definition<br>to reflect increasing certainty of clinical diagnoses<br>in absent of virological confirmation; switch to<br>aggregate data collection on morbidity and<br>mortality. Maintain sufficient virological<br>surveillance to detect antigenic drift. | CE & Directors<br>of Surveillance<br>and DPC.     |
|   | Subsided (end of pandemic or between waves)   |   |
| 1 | Evaluate resource needs for subsequent waves if they occur.   | Directors of<br>EDMSSB and<br>Family Health       |
| 2 | Identify the most effective surveillance and control measures for subsequent pandemic waves.  | CE, Directors of EDMSSB; FH;                      |

|   |   | and Surveillance   |
|---|---|--|
| 3 | Report current status through appropriate international mechanisms.     | CMO; Directors<br>of EDMSSB and<br>Family Health   |
| 4 | Review lessons learned.   | CMO, CE,<br>Directors of<br>EDMSSB, HSPI,<br>Family Health,<br>HP&P EH, VPH;<br>and Vet.<br>Medicine |
| 5 | Reinstate enhanced surveillance for early detection of subsequent wave. | CE, Directors of<br>EDMSSB; and<br>Surveillance  |
| 6 | Share experience gained with international community (lessons learned). | CMO; Directors<br>of EDMSSB and<br>Vet. Medicine   |

| Categ | Category: Prevention and Containment              |                     |  |
|-------|---|---------------------|--|
| Objec | Objectives:                                       |                     |  |
| 1.    | To contain or delay spread using public health ir | nterventions, while |  |
|       | limiting societal disruption.                     |                     |  |
| 2.    | To minimize morbidity and mortality through th    | e rational use of   |  |
|       | pharmaceuticals, eg. Vaccines and antivirals.     |                     |  |
| No.   | ACTIONS   | PERSON(S)           |  |
|       |   | RESPONSIBLE         |  |
|       | As soon as possible (regardless of extent of      |                     |  |
|       | disease activity)                                 |                     |  |
| 1     | Implement pandemic vaccine procurement plans;     |                     |  |
|       | update vaccine recommendations; re-evaluate       | Family Health       |  |
|       | dosage and schedule based on available new data   |                     |  |
|       | and WHO recommendations; plan logistics of        |                     |  |
|       | delivery.   |                     |  |
| 2     | As soon as available, implement pandemic vaccine  |                     |  |
|       | programme as availability/ resources permit;      | Family Health       |  |
|       | evaluate safety and efficacy; monitor supply.     |                     |  |
|       | Countries not yet affected                        |                     |  |

| 1 | Implement appropriate public health interventions<br>as identified during contingency planning and<br>consider new guidance provided by WHO  | Directors of<br>Environmental<br>Health; DPC;<br>VPH and<br>Surveillance |
|---|--|--|
| 2 | Review/update recommendations for use of<br>antivirals based on: emerging data from affected<br>countries; clinical studies; evidence of resistance;<br>changes to WHO recommendations; availability<br>and resources.   | Directors of<br>Family Health<br>and DPC                                 |
| 3 | Implement distribution plan; monitor supply; be<br>prepared to contribute to evaluation of safety and<br>effectiveness.<br>Affected countries – Jamaica affected   | Director of<br>Family Health   |
| 1 | Implement appropriate public health interventions identified during contingency planning, and consider new guidance provided by WHO.   | Directors of<br>Environmental<br>Health; DPC;<br>VPH and<br>Surveillance |
| 2 | When possible, evaluate the effectiveness of such measures.  | Directors of<br>Environmental<br>Health; DPC;<br>VPH and<br>Surveillance |
| 3 | <ul> <li>Re-evaluate use of antivirals based on clinical studies, evidence of resistance, changes to WHO recommendations and availability.</li> <li>Subsided (end of pandemic or between waves)</li> </ul>   | Directors of<br>Surveillance and<br>Family Health                        |
| 1 | Review effectiveness of treatments and counter<br>measures; update guidelines, protocols and<br>algorithms.  | Directors of<br>Family Health;<br>HP&P and<br>HSP&I                      |
| 2 | Evaluate antiviral efficacy, safety and resistance data; review/update guidelines as necessary; assess supply for subsequent wave(s).  | Directors of<br>Family Health<br>and Surveillance                        |
| 3 | Assess vaccines coverage to date, efficacy and<br>safety; review/update guidelines as necessary;<br>begin vaccination of persons not yet immunized in<br>line with plans, priority status and availability;<br>consider incorporation of pandemic strain into<br>seasonal vaccine. | Director of<br>Family Health   |

| Category: Health System Response                                       |  |
|--|--|
| Objectives:  |  |
| 1. To optimize patient care with limited resources.                    |  |
| 2. To reduce overall impact of the pandemic (morbidity and mortality). |  |

To reduce overall impact of the pandemic (morbidity and mortality).
 To manage demand on health systems in order to maximize sustainability

|     | of response.  |  |
|-----|---|--|
| No. | ACTIONS   | PERSON(S)<br>RESPONSIBLE                           |
|     | Countries not yet affected- Jamaica not yet affected  |  |
| 1   | Keep emergency coordinating arrangements and chains of command for health systems fully functional.   | Directors, EDMSSB,<br>HSPI, DPC                    |
| 1.1 | Review WHO declaration and format and prepare new information for distribution  | "  |
| 1.2 | Distribute using lists and guidelines as for Phase 3  | "  |
| 2   | Keep case definition, protocols and algorithms for case-<br>finding, management (including appropriate use of<br>antibiotics to treat suspected bacterial infections),<br>infection control and surveillance updated in line with the<br>latest WHO guidance. | Directors, EDMSSB,<br>HSPI and DPC                 |
| 3   | Maintain health care worker vigilance for the onset of cases and clusters.  | Directors,<br>EDMSSSB, HSPI                        |
| 4   | Finalize ways to provide drugs and medical care free of<br>charge (or covered by insurance) to the patient and the<br>health care delivery system, to encourage prompt<br>reporting and recognition of the start of pandemic activity.                        | HMH, PS, CMO,<br>Director, EDMSSB                  |
| 5   | Maintain capability / capacity for infection control for ill<br>patients and implement infection control consistent with<br>latest WHO guidelines; maintain staff competency in use<br>of personal protective equipment (conduct drills).                     | Director, EDMSSB /<br>RTDs / MOs(H)                |
| 6   | Keep under review plans relevant to health system<br>response at all levels down to the smallest functioning<br>health unit.  | ű  |
| 6.1 | Maintain surge capacity arrangements  | "  |
| 6.2 | Prepare for imminent switch to pandemic working arrangements  | "  |
|     | Affected countries - Jamaica affected   |  |
| 1   | Implement in full, pandemic contingency plans for health<br>systems and essential services at national and local levels<br>where affected.  | Directors, EDMSSB,<br>HSPI, DPC / RTDs /<br>MOs(H) |
| 1.1 | Activate health systems and plans to accept patients at all facilities, according to approved list  | "  |
| 1.2 | Prepare isolation and quarantine facilities to accept patients  | ű  |
| 1.3 | Monitor health system status  | "  |
| 1.4 | Adjust triage system if necessary   | "  |
| 1.5 | Deploy additional workforce and volunteers  | "  |
| 1.6 | Ensure staff support  | "  |
| 1.7 | Provide medical and non-medical support for ill people in alternative (non-health care) facilities, if needed.  | "  |
| 1.8 | Provide social / psychological support for health care workers, victims and communities.  | Directors, HRM&<br>Mental Health                   |
| 2   | Implement data collection system on effectiveness and<br>safety of clinical interventions, as determined, and share<br>these with areas not yet affected and WHO.   | CMO, Dir, EDMSSB                                   |

| 3   | Implement vaccine campaign according to established priority status, in keeping with plans and availability.    | Dir. FH          |
|-----|---|------------------|
| 4   | If resources permit, collect available data on effectiveness of clinical interventions and share these with WHO | CMO, Dir, EDMSSB |
|     | Subsided (end of pandemic or between waves)   |                  |
| 1   | Ensure that overworked staff have opportunities for rest  | RTDs             |
|     | and recuperation  | Director,HRM&CS  |
| 2.1 | Restock medications and supplies  | Dir. FH          |
| 2.2 | Service and renew essential equipment   | Dir. Maintenance |
| 3   | Review / revise plans in anticipation of subsequent waves   | Dir. EDMSSB      |
| 4   | Support rebuilding of essential services  | CMO, Dir, EDMSSB |
| 5   | Adjust case definitions, protocols and algorithms   | "                |
| 6   | Continue with vaccine programme in line with plans, priority order and availability                             | Dir. FH          |

| Category: Communications – (see Appendix XIV) |   |                        |  |
|---|---|------------------------|--|
| Objectives:                                   |   |                        |  |
| 1   | To ensure public access to regularly-updated official nation                | nal sources and focal  |  |
|   | points for credible, consistent information related to the par              | demic.                 |  |
| 2   | To maintain open and accessible channels for advice to                      | the public on specific |  |
|   | subjects (e.g. travel, social gatherings, etc.).                            |                        |  |
| 3   | To achieve public acceptance and support for nati                           | onal responses and     |  |
|   | contingency measures.   |                        |  |
| 4   | 4 To ensure rapid sharing of information regarding progress of the pandemic |                        |  |
|   | among health authorities, other relevant government de                      | epartments and other   |  |
| partners.                                     |   |                        |  |
| No.   | ACTIONS   | PERSON(S)              |  |
|   |   | RESPONSIBLE            |  |
|   | Countries not yet affected – Jamaica not yet affected                       |                        |  |
| 1   | Keep news media, public, professional partners and other                    | Directors of           |  |
|   | stakeholders informed about progress of pandemic in                         | EDMSSB and             |  |
|   | affect countries; prepare audiences for imminent onset of                   | Communication          |  |
|   | pandemic activity.  |                        |  |
| 2   | Redefine key messages; set reasonable public                                | Directors of           |  |
|   | expectations: emphasis need to comply with public health                    | EDMSSB and             |  |
|   | measures despite their possible limitations.                                | Communication          |  |
| 3   | Utilize last "window of opportunity" to refine                              | Directors of           |  |
|   | communications strategies and systems in anticipation of                    | EDMSSB;                |  |
|   | imminent pandemic.  | Communications         |  |
|   |   | and HP&P               |  |

| 4 | Inform public about interventions that maybe modified or  | Directors of       |
|---|---|--------------------|
|   | implemented during a pandemic, e.g. prioritization of     | EDMSSB; HSP&I      |
|   | health-care services and supplies, travel restrictions,   | HP&P and           |
|   | shortages of basic commodities, etc.                      | Communications     |
|   | Affected countries – Jamaica affected                     |                    |
| 1 | Maintain capacity for meeting expected domestic and       | Directors of       |
|   | international information demands.                        | EDMSSB; HP&P/      |
|   |   | CE                 |
| 2 | Activate all elements of the communications plan.         | Directors of       |
|   |   | EDMSSB and         |
|   |   | Communications     |
| 3 | Acknowledge public anxiety, grief and distress associated | Director of        |
|   | with pandemic.  | EDMSSB; HP&P       |
|   | •   | HRM and            |
|   |   | Communication      |
| 4 | Audit outcomes of communications activities to refine     | Directors of       |
|   | current response and inform future pandemic planning.     | EDMSSB;            |
|   |   | Communications     |
|   |   | and HP&P           |
|   | Subsided (end of pandemic or between waves)               |                    |
| 1 | Evaluate communications response during previous          | CMO/ CE/ Directors |
|   | [phases; review lessons learned                           | of EDMSSB; Family  |
|   |   | Health; HSP&I,     |
|   |   | HP&P VPH & Vet.    |
|   |   | Medicine           |
| 2 | Publicly address community emotions after the pandemic.   | Director of        |
| _ |   | EDMSSB; HP&P       |
|   |   | and Communication  |
| 3 | Make people aware of uncertainties associated with        | Directors of       |
|   | subsequent waves.   | EDMSSB;            |
|   |   | Communications     |
|   |   | and HP&P           |
|   |   | anu nfaf           |

#### **VI. DEACTIVATION**

Deactivation will be declared by the CMO or the SMO(H) / Director, EDMSS on the advise of the CMO, when it has been determined that all actions have been taken in the Response to prevent and control the transmission of Influenza. Incidence would have returned to determined endemic levels and all follow-up actions for the Response completed.

#### VII. RECOVERY

Actions in this phase will return programmes, projects and plans of all sectors to those routine activities, which were in place before the Response to the Influenza Pandemic.

#### VIII. DEBRIEFING

A debriefing meeting for the MOH will be convened by the SMO(H) / Director, EDMSS within seven (7) working days of deactivation.

Debriefing meetings at the level of the institution, parish and region are also to be held, prior to the MOH debrief and all reports forwarded at least three (3) days before the MOH debrief.

For prolonged activations, debriefing meetings and reports will be held periodically as outlined in the MOH NEOC Plan and as requested by the HMH.

#### IX. FINAL REPORT

A final report will be prepared by the SMO(H) / Director, EDMSS within fourteen (14) working days of deactivation and ten (10) working days of the debriefing meeting.

Acknowledgements: Thanks to all who assisted in the preparation of this Plan and the Appendices. Special mention must be made of the assistance from Drs. Denise Duncan Goffe, Linnette Peters, Erica Reynolds Hedmann, Colette Cunningham Myrie, Karen Lewis Bell, Evadne Williams and Judith Kirlew.